Elucidating the role of growth rate on the production of a fusion protein under regulation of the hp4d promoter by Yarrowia lipolytica by Govender, Seshni
Elucidating the role of growth rate on the production 
of a fusion protein under regulation of the hp4d 







Thesis presented in fulfilment of the requirements for the degree of Master of Science 
(Microbiology) in the Faculty of Science at the University of Stellenbosch 
 
Supervisor:  Prof W.H. van Zyl 
                          Co-supervisors:         Dr P.J. van Zyl 










By submitting this thesis, I, Seshni Govender,
therein is my own, original work, that I am the sole author thereof (save to the extent explicitly 
otherwise stated), that reproduction and publication thereof by Stellenbosch University will not 
infringe any third party rights and that I have not previously in its entirety or in part submitted it 






















Presentation given at the SASM Conference 2013, Bela Bela, South Africa: 
Title: Effect of growth rate on the production of a pharmaceutical precursor peptide regulated by 
the hp4d promoter in Yarrowia lipolytica. SASM Conference   
S Govender, M Crampton, SI Bulani, WH van Zyl and PJ van Zyl  
 





Firstly, I would like to thank God for his guidance and protection throughout my MSc studies. In 
the undertaken of this research project, there have been many individuals whom have 
contributed greatly; it gives me absolute pleasure to acknowledge them in this dissertation.  
 
To my supervisor, Prof W.H. van Zyl (Emile), thank you for giving me this opportunity to 
conduct my MSc studies. Your assistance throughout my research project is highly appreciated.    
 
To Dr Petrus van Zyl, my mentor and co-supervisor at the Council for Scientific and Industrial 
Research (CSIR), thank you for all the long hours you put into my research project and for the 
motivation you gave me during all my experiments. Your passion, guidance and expertise have 
made me into the researcher I am today.  
 
To Dr Michael Crampton, thank you for your time, effort, expertise and support you have 
displayed throughout my research project 
 
My sincere gratitude also goes out to Dr Robyn Roth and Dr Fritha Hennessey for the positive 
feedback in reviewing my dissertation. To Dr Daniel Visser, Dr Siyavuya Ishmael Bulani and Dr 
Faranani Ramagoma thank you for the assistance throughout my research project. 
 
To my friends and colleagues at the CSIR, especially, Thea Hanekom, Magdalien Bannister, 
Tina Ronneburg, Mpho Mamabolo, Vishani Lukman, Shivani Goolab, Nokulunga Miama, Taola 
Shai, Gugu Ngwenya, Nodumo Zulu, Aversh Parsoo, Yrielle Roets, Ghaneshree Moodley and 
Monique Smith, thank you for assistance and support you have given to me.   
 
Stellenbosch University  https://scholar.sun.ac.za
iv 
 
To the technical staff at the Biosciences Department at the CSIR, Mrs Daphney Mabena and Mr 
Harris Manchidi, thank you for the assistance and support you have provided me over the years.  
 
I would also like to acknowledge the CSIR for giving me the opportunity to do my MSc 
studentship and DST - NRF (Department of Science and Technology - National Research 
Foundation) for funding of this project.  
 
To Pragesh and Daisy Govender, thank you for all the love and support you have given me 
during the completion of this project. To Julian Govender, Sunaina Indermun, Sarusha Naidoo, 
Rushil Ahir, Thevashnee Pillay, Suveer Ramshayee, Nerusha Naidoo and Kimantha Naidoo, 
thank you for all support and motivation. 
 
Finally to my family (to whom I dedicate this thesis to) , my parents Arunajallam (Tilo) and Kogie 
Govender, my brother Mershen and my boyfriend Viren, words cannot highlight the amount of 
love, effort, dedication, motivation and support you have provided me over the years.  







To my Family: 
 Arunajallam (Tilo), Kogie, Mershen and Viren Govender 
for the love and support you have afforded me in the undertaken 
and compilation of this research project 





Exenatide (Byetta®) is a type 2 diabetic drug which decreases the blood glucose level. 
Treatment using this drug is expensive due to its costly production by chemical synthesis 
therefore it is not an affordable drug of choice. A potential cost effective alternate for the 
production of exenatide is the use of recombinant production technology. Yarrowia lipolytica, a 
dimorphic yeast, was genetically engineered to produce the exenatide peptide (Exe, 39 amino 
acids) as a fusion to Lip2 (lipase) protein under the regulation of the hp4d promoter by the 
CSIR. The regulation of the promoter has, until recently, not been elucidated and is currently 
reported to be growth phase dependent. In order to optimise the conditions for the production of 
the fused Lip2:Exe peptide precursor, the regulation of the promoter needed to be understood. 
 
In this study, the regulation of the hp4d promoter was established and a fed-batch fermentation 
strategy for the production of the fused Lip2:Exe precursor was developed. A Y. lipolytica strain 
(YlEx-gly) producing the Lip2:Exe peptide was cell-banked (to ensure stability of the production 
organism and repeatability of inoculation of fermenters) and the cell-bank was validated for 
production of the fused peptide. A transcript profile of the recombinant strain harbouring an 
expression vector encoding the Lip2:Exe under control of the hp4d promoter was determined 
using an optimised mRNA sandwich hybridisation methodology. Batch fermentation (1.2 l) was 
used to monitor production profiles during growth of Y. lipolytica followed by continuous 
fermentation (1 l) to determine the effect of growth rate on the transcription levels of the product 
under regulation by the hp4d promoter.  
 
The synthetic hp4d promoter was found to be growth rate dependent which was confirmed by 
quantifying the amount of total protein produced during fed-batch fermentations (10 l) at 
different growth rates. A 60 % increase in production yields was achieved by using the 
optimised growth rate of 0.02 h-1. This validated that the hp4d is growth rate dependent and not 
growth phase dependent as reported in literature. A strategy for the recombinant production of 
pharmaceutical peptides and proteins, under regulation of the hp4d promoter, using Y. lipolytica 
as a host, was therefore established. This research has paved the way for recombinant 
production of proteins at a lower cost therefore impacting on the health and economy of South 
Africa, by providing the public with potentially cheaper, affordable pharmaceutical drugs due to 
an alternative production strategy. 





Exenatide (Byetta®) is a middle wat vir die behandeling van tipe 2 diabete gebruik word deur die 
bloed glucose konsentrasiete verlaag. Hierdie behandeling is egter baie duur aangesien dit 
chemiesvervaardig word en dus nie bekostigbaar vir alle pasiente is nie. ‘n Bekostigbare 
alternatiewe vervaardigingsmetode is die gebruik van rekombinante produksie. Yarrowia 
lipolytica is ‘n dimorfiese gis wat geneties gemanipuleer is om exenatide (Exe, amino sure) as ‘n 
fusieproduksaam met die Lip2 (lipase) proteïen onder regulering van die hp4d promoterte 
produseer. Die regulering van die promoter is onbekend endit word aanvaar dat uitdrukking 
afhanklik is van die groeifase. Om produksie van die Lip2:Exe peptiedvoorloper te optimiseer is 
dit belangrik om die regulering van die promoter te verstaan.  
 
In die studie is die reguleering van die hp4d promoter bepaal en ‘n voerstrategie vir die 
produksie van die Lip2:Exe peptiedvoorloperin voer-lotfermentasie ontwikkel. ‘nY. lipolytica 
kloon (YlEx-gly) wat die Lip2:Exe peptiedvoorloper produseer is in ‘n selbank gepreserveer om 
die stabiliteit van die produksie organisme en herhaalbaarheid van die inokulasie van die 
fermenteerders te verseker) en die selbank is getoets vir produksie van die fusiepeptied. ‘n 
Transkripsie profiel van ‘n positiewe kloon wat die hp4d uitdrukkings vector, 
(pKOV410:Lip2:Exe) bevat, is bepaal deur van ‘n geoptimiseerde mRNA toebroodjie 
hibridisasiemetodegebruik te maak. Lotfermentasies (1.2 l) was gebruik om die produksieprofiel 
gedurende groei van Y. lipolytica te bepaal. Kontinüe fermentasie (1 l) is gebruik om die effek 
van groeitempo op die transkripsievlakke van die produk onder reguleering van die hp4d 
promoter te bepaal.  
 
Dit is vasgestel dat die reguleering van die sintestiese hp4d promoter onderhewig is aan die 
groei tempo van die organisme.  Dit is bevestig deur die bepalingvan die hoeveelheid totale 
proteïen wat geproduseer is in 10 l voer-lotfermentasies wat teen verskillende groeitempos 
uitgevoer is. ‘n Sestig present toename in produksie is teweeggebring deur die organsisme teen 
‘n groeitempo van 0.02 h-1 te laat groei. Dit het bevestig dat die reguleering van die hp4d 
promoter onderhewig is aan die groeitempo en nie die groeifase soos in literatuur genoemis nie. 
‘n Strategie vir die rekombinante produksie van farmaseutiese peptiede en proteïen onder 
beheer van die hp4d promoter deur Y. lipolytica is dus ontwikkel. Hierdie navorsing lê die 
grondslag vir goedkoper rekombinante produksie van proteïen. Hierdie tegnologie kan ‘n 
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positiewe invloed hê op gesondheid en die ekonomie van Suid Afrika deur die daarstelling van 




ARS:    Autonomously Replicative Sequence  
BBTP:   2'-[2-benzothiazoyl]-6'-hydroxybenzothiazole phosphate 
BBT:   2'-[2-benzothiazoyl]-6'-hydroxybenzothiazole 
BIDC:   Biomanufacturing Industry Development Centre 
Bp:   base pair  
BSA:   Bovine Serum Albumin 
CHO:    Chinese hamster ovary cells 
CSIR:   Council for Scientific and Industrial Research 
DCW:   Dry Cell Weight 
DIG:   Digoxigenin  
DNA:   Deoxyribonucleic acid 
DO:   Dissolved Oxygen 
ECS:   Entrokinase Cleavage Site 
Exe:   Exenatide  
FDA:   Food and Drug Administration 
GRAS:   Generally Regarded As Safe 
His:   Histidine  
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HIV:   Human Immunodeficiency Virus  
hp4d:   hybrid promoter derived (four tandem repeats) from the XPR2 promoter 
IPA:   Isopropyl Alcohol 
leu:   leucine 
LEU2:   β-isopropylmalate dehydrogenase 
Lip2:    Endogenous lipase 
mRNA:  messenger RNA 
OD660:    Optical density at wavelength 660 nm 
PCA:   Plate Counting Agar  
pNP:   p-nitrophenol  
pNPP:    p-nitrophenyl palmitate  
RNA:   Ribonucleic acid 
slpms:   Standard liters per minute  
UAS1:   Upstream Activating Sequence  
Ura:   Uracil  
XPR2:   Alkaline extracellular protease 
YPD:   Yeast Peptone and Dextrose 
Stellenbosch University  https://scholar.sun.ac.za
x 
 
List of Figures 
 
Figure 1: Gap present in the pharmaceutical industry potentially filled by peptides .................... 8 
Figure 2: Peptide synthesis using liquid phase chemistry ..........................................................10 
Figure 3: Global market for recombinant protein drugs ..............................................................11 
Figure 4: Percentage of protein-based recombinant pharmaceuticals, produced by different 
expression systems ..................................................................................................................12 
Figure 5: Advantages and disadvantages during recombinant protein production by E. coli ......13 
Figure 6: The pKOV410 plasmid containing the Lip2-Exe fusion gene was randomly integrated 
into the genome of Y. lipolytica. ................................................................................................23 
Figure 7: The Lip2:Exe expression cassette integrated into the genome of Y. lipolytica. ...........28 
Figure 8: Confirmation of monoseptic culture ............................................................................33 
Figure 9: Growth of Y. lipolytica (YlEx-gly) in 2.5 l (n=5) flasks.. ................................................34 
Figure 10: Validation of cell banked Y. lipolytica (YlEx-gly) for the recombinant production of 
extracellular lipase in Ultra Yield Flasks (n=5, 2.5 l).. ................................................................35 
Figure 11: Validation of the production of extracellular fused Lip2:Exe precursor peptide by Y. 
lipolytica in batch fermentation. .................................................................................................37 
Figure 12: Total extracellular protein production profile by Y. lipolytica (YlEx-gly). ....................38 
Figure 13: Modified schematic diagram showing mRNA sandwich hybridisation assay. ............41 
Figure 14: Portion of Lip2:Exe sequence indicating the binding positions of four complementary 
probes. ......................................................................................................................................42 
Figure 15: Detection of PCR product using agarose gel electrophoresis.. .................................52 
Stellenbosch University  https://scholar.sun.ac.za
xi 
 
Figure 16: Detection of transcribed PCR product using formaldehyde agarose gel 
electrophoresis.. ........................................................................................................................52 
Figure 17: Comparison of three different protocols using different hybridisation solutions and two 
different magnetic bead concentrations 50 µg () and 20 µg () concentrations used to 
optimise the mRNA sandwich hybridisation assay.. ..................................................................55 
Figure 18: Variation of Fluorescence intensity after cell breakage of Y. lipolytica cells during 
cultivation in Ultra yield (2.5 l) flasks. ........................................................................................56 
Figure 19: Replicates of a sample using different cell breakage solutions. ................................56 
Figure 20: Growth profile () and validation of mRNA sandwich hybridisation assay protocol () 
during shake flask production of Lip2:Exe fusion by Y. lipolytica ...............................................58 
Figure 21: The effect of different glucose concentrations on the growth of Y. lipolytica (YlEx-gly) 
in shake flasks at 20 g.l-1 yeast extract concentration.. ..............................................................65 
Figure 22: The effect of growth rate on biomass and Lip2: Exe production by Y lipolytica (YlEx-
gly) grown in continuous fermentation. ......................................................................................67 
Figure 23: The effect of growth rate (dilution) on transcription and translation during production 
of Lip2:Exe fusion by Y. lipolytica (YlEx-gly) under regulation of the  hp4d promoter.................68 
Figure 24: Fed-batch fermentation of Y. lipolytica (YlEx-gly) expressing fused Lip2:Exe at 
different growth rates.. ..............................................................................................................70 
Figure 25: Total extracellular protein production and optical density during fed-batch 
fermentation at different growth rates.. ......................................................................................71 
Figure 26: Comparison of extracellular protein production of Y. lipolytica during Fed-Batch and 
Continuous fermentation.. .........................................................................................................72 
 
Stellenbosch University  https://scholar.sun.ac.za
xii 
 
List of Tables 
 
Table 1: List of some the proteins heterologously produced by Bacili strains ............................16 
Table 2: Comparison of hirudin production using different expression systems .........................19 
Table 3: Promoters available for Y. lipolytica and their characteristics. .....................................24 
Table 4: Characteristics of Y. lipolytica strain and plasmid containing the Lip2:Exe fusion 
peptide. .....................................................................................................................................28 
Table 5: Lipase Assay components used to quantity the amount of fused Lip2:Exe produced. .31 
Table 6: Complementary mRNA probes designed for sandwich hybridization assay. ................42 
Table 7: Primers used for PCR reaction of Lip2:Exe DNA fragment ..........................................43 
Table 8: PCR reaction to generate standards for mRNA hybridisation assay. ...........................44 
Table 9: Components of hybridization solution used to optimise mRNA assay. .........................48 
Table 10: Different buffers evaluated  for cell breakage. ...........................................................50 
Table 11: Media composition for determining glucose limitation ................................................62 
 





Declaration ................................................................................................................................... i 
Research Output ......................................................................................................................... ii 
Acknowledgements .................................................................................................................... iii 
Abstract...................................................................................................................................... vi 
Opsomming .............................................................................................................................. vii 
Abbreviations ........................................................................................................................... viii 
List of Figures ............................................................................................................................. x 
List of Tables ............................................................................................................................ xii 
 
Chapter 1: Introduction and Hypothesis of Study ....................................................................... 1 
1.1 Introduction .............................................................................................................. 2 
1.2 Hypothesis of Study ................................................................................................. 5 
1.3 Outline of thesis ........................................................................................................ 6 
 
Chapter 2: Literature Review ...................................................................................................... 7 
2.1 Importance of peptide base therapeutics in the pharmaceutical Industry .................. 8 
2.2 Chemical synthesis of peptides in the pharmaceutical industry ................................ 9 
2.3 Recombinant production of peptides in the pharmaceutical industry ........................10 
2.4 Bacterial expression systems ..................................................................................12 
2.5 Plant expression systems ........................................................................................17 
2.6 Mammalian expression systems ..............................................................................18 
2.7 Yeast expression systems .......................................................................................19 
2.8 Yarrowia lipolytica ...................................................................................................21 
2.9 Concluding Remarks ...............................................................................................25 
Stellenbosch University  https://scholar.sun.ac.za
xiv 
 
Chapter 3: Evaluation of Yarrowia lipolytica (YlEx-gly) expressing a pharmaceutical peptide 
precursor under regulation of the hp4d promoter ......................................................................26 
3.1 Introduction .............................................................................................................27 
3.2 Materials and Methods ............................................................................................28 
3.3 Results and Discussion ...........................................................................................33 
3.4 Concluding Remarks ...............................................................................................38 
 
Chapter 4: Optimisation of a mRNA sandwich hybridisation methodology for Lip2:Exe transcript 
quantification .............................................................................................................................39 
4.1 Introduction .............................................................................................................40 
4.2 Materials and Methods ............................................................................................42 
4.3 Results and Discussion ...........................................................................................51 
4.4 Concluding Remarks ...............................................................................................58 
 
Chapter 5: Determining the effect of growth rate on the regulation of the hp4d promoter by 
monitoring mRNA transcription .................................................................................................59 
5.1 Introduction .............................................................................................................61 
5.2 Materials and Methods ............................................................................................62 
5.3 Results and Discussion ...........................................................................................64 
5.4 Concluding Remarks ...............................................................................................73 
 
Chapter 6: Conclusion and Future Recommendations ..............................................................74 
6.1 Conclusion ..............................................................................................................75 
6.2 Future Recommendations and research outputs .....................................................76 
 
Chapter 7: References ..............................................................................................................77 










Chapter 1: Introduction and 
Hypothesis of Study 





The complex processes required for chemical synthesis of peptides have been studied for 
several decades providing crucial understanding necessary for production of proteins in the 
pharmaceutical industry. This has played an important role in the discovery of drugs necessary 
for the treatment of diseases. One of the shortcomings in the multi-national pharmaceutical 
industry is the costly chemical synthesis of drugs. On average, drugs like Enfuvirtide (Fuzeon®), 
a Human Immunodeficiency Virus (HIV) fusion inhibitor, requires 106 steps to manufacture 
(Bray, 2003). This in turn has a large impact on the consumer, especially for a third-world 
country such as South Africa. There is, however, a cost effective alternative for pharmaceutical 
peptide manufacturing that exists known as recombinant production. 
 
Heterologous gene expression has, for decades, been used for the production of 
pharmaceutical peptides and enzymes such as insulin, mammalian chymosin and Penicillin G 
acylase (Cowan, 1996, Yang et al., 2001, Ferrer-Miralles et al., 2009; Martínez et al., 2012). 
There are several expression systems that are commonly used such as bacteria, yeast, plants, 
mammalian cells and transgenic animals. When choosing a host system, one needs to consider 
the following: cell growth characteristics of the organism, the expression levels, secretion 
location (intracellular, extracellular or both), posttranslational modifications and the 
characteristics of the recombinant protein of interest (Goeddel, 1990; Hodgson, 1993; Makrides, 
1996).   
 
Yeast expression systems, in particular Yarrowia lipolytica, have widely generated interest in the 
field of recombinant protein production. Several Y. lipolytica processes have been classified as 
GRAS (Generally Regarded As Safe) by the American Food and Drug Administration (Madzak 
et al., 2000). A large number of molecular tools are available for recombinant protein expression 
by Y. lipolytica and it has been described as one of the most promising yeasts available as a 
host for heterologous protein production (Müller et al., 1998). 
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A number of promoters are available for recombinant protein production by Y. lipolytica. This 
organism can produce between 1-2 g.l-1 of alkaline extracellular protease (AEP) which is 
encoded by the XPR2 gene (Tobe et al., 1976, Ogrydziak and Scharf, 1982; Barth and 
Gaillardin, 1997, Madzak et al., 2004). XPR2 (alkaline extracellular protease) gene has a strong 
constitutive promoter with a complex regulation mechanism. It is only active at a pH above 6 
and requires high levels of peptone for induction (Madzak et al., 2004).  The XPR2 promoter 
was analyzed and an upstream activating sequence (UAS1) region was found not to be 
significantly affected by environmental conditions such as specifically defined medium 
requirements and pH (Blanchin-Roland et al., 1994; Madzak et al., 1999).  This UAS1 fragment 
was used to design a synthetic promoter called hp4d by placing four copies of the UAS1 
fragment in tandem, upstream from a LEU2 (β-isopropylmalate dehydrogenase) promoter 
(Madzak et al., 1995; Madzak et al., 2000). The hp4d promoter’s regulation mechanism is 
independent of pH, carbon, nitrogen or peptone levels in medium and is able to drive strong 
expression levels of proteins (Madzak et al., 1995; Madzak et al., 2000). According to literature 
the hp4d promoter is quasi-constitutive and its regulation is growth-phase dependent and it is 
switched on during the early stationary growth phase (Madzak et al., 2004; Madzak et al., 
2000).  
 
A number of proteins have been produced by the Council for Scientific and Industrial Research 
(CSIR) using Y. lipolytica as a host organism. These include the enzymes, epoxide hydrolase 
from Rhodotorula araucariae (Maharajh et al., 2008), endo-ß-1, 4-mannanase from Aspergillus 
aculeatus (Roth et al., 2009), the Human Immunodeficiency Virus (HIV) fusion inhibitor, 
Enfuvirtide (unpublished data) and a galactose oxidase M1 enzyme, a camelid antibody 
fragment and a trypsin inhibitor by Hofmeyer et al., (2014).  The last four products were fused to 
the native Lip2 (endogenous lipase) gene and expressed as fusion precursor peptides. 
Extracellular Lip2, a native lipase enzyme, was shown to reach high levels in the medium when 
secreted by Y. lipolytica (Pignede et al., 2000a; Pignede et al., 2000b; Fickers et al., 2005; 
Hofmeyer et al., 2014). The secretion signal used for the pre-pro Lip2 (Pignede et al., 2000a; 
Pignede et al., 2000b) allows direct secretion into the culture medium. Hofmeyer et al. (2014) 
expressed several recombinant proteins using Lip2 as a fusion partner. All of the proteins were 
produced under regulation of the hp4d promoter.   
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The CSIR is developing a process for the recombinant production of pharmaceutical peptides 
using Y. lipolytica as a host. In order to optimise conditions for heterologous protein production 
by Y. lipolytica, the production using the hp4d promoter needed to be optimised. The production 
of Lip2, one of the most highly secreted enzymes by Y. lipolytica, under regulation of the hp4d 
promoter was previously elucidated in continuous fermentation and found to be linked to growth 
rate with high production yields occurring at growth rates lower than 0.045 h-1 (van Zyl, 2013). 
However this does not explain if growth rate has an effect on the regulation of the hp4d 
promoter (transcription) or at the level of cellular metabolism where lower growth rates would 
allow metabolism to shift from biomass production to product formation.  
 
In this study, the Y. lipolytica Po1f host strain was genetically engineered to produce the 
exenatide peptide (39 amino acids) as a fusion to the Lip2 gene under the regulation of the 
hp4d promoter. Exenatide (Byetta®) was the drug chosen due to the expensive processes 
associated with its production (Chapter 3). A cell bank of the production strain (to ensure strain 
stability) was generated and the cell bank was validated by measuring total recombinant protein 
production and lipase activity (used as a reporter enzyme) in shake flask cultivation and batch 
fermentation. This cell bank was used to determine the effect of growth rate on transcription 
levels of the gene under regulation of the hp4d promoter. The level of transcription was 
quantified by using a sandwich hybridisation assay which has been described as “ideal” for 
quantifying mRNA in bacterial and yeast cells during fermentation (Rautio et al., 2003). The 
hybridisation solution for this assay and cell breakage was optimised and validated to ensure 
reproducibility. Y. lipolytica was cultivated in continuous fermentation at different growth rates 
using carbon limitation as the growth regulator and the level of transcription and product 
formation was determined at the different growth rates. The data obtained from the continuous 
fermentation was validated in fed batch fermentations by controlling the feed rate to maintain 
the desired growth rates during production of Lip2:Exe fused product. 
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1.2 Hypothesis of Study 
 
The production of a pharmaceutical peptide precursor under regulation of hp4d 
promoter, by Yarrowia lipolytica, is growth rate dependent and is regulated at the level of 
transcription. 
In order to prove this hypothesis, the following objectives were met: 
Evaluation of a Yarrowia lipolytica construct expressing a pharmaceutical peptide precursor 
under regulation of the hp4d promoter: 
 Cell banking of Y. lipolytica (YlEx-gly) expressing the fused Lip2:Exe precursor  
 Growth curve study and validation of the cell bank for production of the fused Lip2:Exe 
precursor  
 Batch fermentation of Y. lipolytica 
 
Optimisation of methodology to monitor mRNA transcription by the hp4d promoter: 
 Generation of mRNA oligonucleotide probes for sandwich hybridization assay 
 Generation of standards for mRNA sandwich hybridization assay 
 Optimization of mRNA sandwich hybridization method 
 Optimization of cell breakage 
 Shake flask study to evaluate the mRNA sandwich hybridization assay for repeatability 
 
Determining the effect of growth rate on the regulation of the hp4d promoter by monitoring 
mRNA transcription 
 Determination of carbon to nitrogen ratio to achieve carbon limitation 
 Evaluation of the effect of growth rate on regulation of the hp4d promoter in continuous 
fermentation  
 Validation of the regulation of the hp4d promoter using a growth-rate limiting fed-batch 
fermentation strategy 
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1.3 Outline of thesis 
 
Chapter 1: This chapter is the introduction to the thesis. It provides a background and 
discusses the rationale for the study. The hypothesis and objectives are also provided. 
Chapter 2: This chapter gives a literature review of recombinant protein production. The 
different types of hosts and promoter systems are compared. An insight in Y. lipolytica, the 
different promoters available for heterologous gene expression and some of recombinant 
proteins produced thus far are highlighted. 
Chapter 3: This chapter displays the evaluation of Y. lipolytica (YlEx-gly) expressing a 
pharmaceutical peptide precursor under regulation of the hp4d promoter.  
Chapter 4: This chapter involves the optimisation of a methodology to monitor mRNA 
transcription under regulation of the hp4d promoter using Y. lipolytica. 
Chapter 5: This chapter details the effect of growth rate on the regulation of the hp4d promoter 
by monitoring mRNA transcription. Subsequently a fed-batch strategy for the production fused 
Lip2:Exe is established.  
Chapter 6: This chapter provides the conclusion and future recommendations for this study.  



















Stellenbosch University  https://scholar.sun.ac.za
8 
 
2.1 Importance of peptide base therapeutics in the pharmaceutical 
Industry 
 
Peptides play an important role in the pharmaceutical market. In comparison to proteins, they 
can be described as molecules consisting of less than 50 amino acids (Craik et al., 2013). A gap 
(Figure 1) between molecules less than 500 Da and biologics of more than 5000 Da exist in the 
pharmaceutical industry and by the use peptides as therapeutics potentially offers to address 
this gap (Craik et al., 2013). There are several peptides that form part of the top selling 
injectable therapeutics in the pharmaceutical industry such as for the treatment of multiple 
scleorsis, worth $3 billion, the immunomodulator Copaxone or glatiramer acetate peptide 
consisting of 10 amino acids; for the treatment of prostate and breast cancer, the peptide 
Zoladex or goserelin, worth $1.1 billion, consisting of 9 amino acids and for multiple myeloma, 
the peptide Velcade or bortezomib, a proteasome inhibitor, worth $1.5 billion, consisting of 2 




Figure 1: Gap present in the pharmaceutical industry potentially filled by peptides (reproduced from Craik 
et al., 2013) 
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Several advantages as to why peptides are important to patients include high binding specificity 
for target sites, low levels of accumulation in tissues, high biological and chemical diversity, 
large range of targets and since peptides form part of proteins which are expressed by 
individuals, each therapeutic treatment can be modified to suit the needs of the patient (Craik et 
al., 2013). However, one needs to consider the disadvantages as well. The oral bioavailabilty of 
peptides can be low, their metabolic stability can be described as low and depending on the 
peptide itself, solubility can be limited (Craik et al., 2013). One of the biggest challenges that 
exist in the pharmaceutical industry is the high production costs associated with the 
manufacturing of these therapeutic peptides. The larger the peptides, the more amino acids are 
required for chemical synthesis resulting in additional production steps. This will be discussed 
further in the next section. 
 
2.2 Chemical synthesis of peptides in the pharmaceutical industry 
 
Over the last two centuries, numerous major developments in the pharmaceutical industry have 
taken place, from the discovery of the first protein vaccine produced for cow-pox, by Jenner in 
1796, to by the first pharmaceutically produced protein insulin, by Banting and Best in 1922 
(Demain and Vaishnav, 2009), to the discovery of the first antibiotic penicillin, by Alexander 
Flemming in 1928 (Brown, 2004; Martínez et al., 2012). The pharmaceutical market is a 
booming sector with several new drugs frequently emerging. In 2008, it was estimated that the 
market was worth $8.5 billion (Moorcroft, 2009).  The production of peptides allow for high 
specificity for treatment of illness although the costly synthesis and bioavailability continues to 
be a problem (Russell, 2012).This high cost price tag is mainly due to the numerous chemical 
steps required during the manufacturing process using solid and liquid-phase chemistry (Figure 
2). Synthesis of peptides is crucially dependent on the sequence, where complexity of solubility 
and racemisation problems arise (Thayer, 2011). The bigger the peptide, the more amino acids 
are required with the possibility of impurities occurring within the synthesised drug (Thayer, 
2011). 
 




Figure 2: Peptide synthesis using liquid phase chemistry (Russell, 2012) 
 
On average, drugs like Enfuvirtide (Fuzeon®), a Human Immunodeficiency Virus (HIV) fusion 
inhibitor, requires 106 steps to manufacture (Bray, 2003). However, a cost effective alternative 
for manufacturing recombinant drugs exists, using heterologous gene expression. There are 
several host organisms available that are capable of producing large quantities of recombinant 
peptides and these will be discussed in detail. 
  
2.3 Recombinant production of peptides in the pharmaceutical 
industry 
 
Heterologous expression has provided an alternative to costly chemical synthesis of 
pharmaceutical peptides and enzymes. For several years, both prokaryotic and eukaryotic 
organisms have been used for production of recombinant therapeutic peptides and naturally 
available biopharmaceuticals and this has created massive interest in the pharmaceutical area 
(Faye and Gomord, 2010).  
 
Production of enzymes found predominately in pathogenic or toxin-producing species could now 
be recombinantly expressed by different hosts making it easier and safer to obtain (Demain and 
Vaishnav, 2009). Some natural products cannot be made using chemical synthesis and it can 
be difficult to isolate them from natural sources hence recombinant protein expression would 
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serve as an ideal alternative for production (Naseby et al., 2009). Insulin was the first 
recombinantly produced protein to enter the pharmaceutical market and was expressed by E. 
coli during the early 1980’s and approved by the American Food and Drug Administration 
(Ferrer-Miralles et al., 2009; Martínez et al., 2012).  Recombinant DNA technology has therefore 
had an effect on the pharmaceutical and enzyme industry making it possible for the recombinant 
production of pharmaceutical peptides, vaccines and enzymes using microbial fermentation 
(Falch 1991). 
 
In 2002, over 155 vaccines and pharmaceutical proteins were approved and developed by 
biopharmaceutical companies (Demain and Vaishnav, 2009).  In 2007, 25% of the 
pharmaceutical market comprised of recombinant therapeutic drugs (Redwan, 2007).  In 2010, 
sales of biopharmaceuticals exceeded 100 billion dollars (Goodman, 2009).  By 2014 (Figure 3), 




Figure 3: Global market for recombinant protein drugs (reproduced from Goodman, 2009, Martínez et al., 
2012) 
 
There are several expression systems (Figure 4) that are currently being used for recombinant 
protein production and these include bacterial, plant, mammalian and yeast hosts (Faye and 
Gomord, 2010).  Several factors need to be considered before choosing an expression host 
including cell growth characteristics of the organism, the expression levels, secretion location 
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(intracellular, extracellular or both), posttranslational modifications and the characteristics of the 
recombinant protein of interest (Goeddel, 1990; Hodgson, 1993; Makrides, 1996).   
 
 
Figure 4: Percentage of protein-based recombinant pharmaceuticals, produced by different expression 
systems (reproduced from Ferrer-Miralles et al., 2009) 
 
There is no ‘universal’ expression system that can be used to achieve high recombinant protein 
yields and as the demand for more complex therapeutic peptides or proteins grow, the search 
for new expression systems for recombinant production continues (Verma et al., 1998; Faye 
and Gomord, 2010). Bacterial host systems are the easiest to manipulate and have been used 
for expression of smaller proteins whereas mammalian cells and yeast systems are used for 
expression of more complex proteins i.e. post-translational modification requirements such as 
disulphide bond formation or glycosylation (Demain and Vaishnav, 2009).   
 
2.4 Bacterial expression systems 
 
Bacterial systems are a common host of choice due to easy manipulation and offer a cheaper 
option for producing the large amounts of protein necessary for industrial, research and 
commercial use (Georgiou and Valax, 1996).  Escherichia coli (E. coli) is a gram negative 
bacterium and is the most exploited expression system used for recombinant protein production 
(Ferrer-Miralles et al., 2009).   
 
The main reasons are: E. coli has the ability to achieve 100 g.l-1 biomass (dry cell weight) using 
high cell density culture systems (fermentation) for the production of recombinant proteins 
(Hannig and Makrides, 1998), several molecular tools available for genetic manipulation, its 
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genomes and metabolic pathways are annotated, capable of achieving high cell density, ability 
to grow fast and up to 80 % of its dry cell weight can consist of the protein of interest (Panda, 
2003; Tripathi et al., 2009; Porro et al., 2011; Martínez et al., 2012). There are a large number 
of cloning vectors and strains  available for heterologous protein production, in particular E. coli 
expression hosts BL21 and K12, (Terpe, 2006) and only minimal amounts of foreign DNA is 
required for transformation (Verma et al., 1998).  In comparison to mammalian cells, E. coli 
grows faster allowing purification; analysis and marketing of the recombinant protein in shorter 
period of time (Verma et al., 1998).   
 
There are several advantages and disadvantages when using E. coli as a recombinant 
expression system and these are summaried in Figure 5. 
 
Figure 5: Advantages and disadvantages during recombinant protein production by E. coli (reproduced 
from Hanning and Makrides, 1998) 
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One of the common drawbacks is, bacterial systems often produce low levels of recombinant 
protein. Other limitations include: large proteins are produced in an insoluble form, proteins 
cannot be released into the culture medium due to the lack of a secretion mechanism, limited 
capacity for facilitating extensive disulphide bond formation, inability to fold proteins into their 
native state resulting in protein degradation or inclusion body formation and its inability to 
perform  complex post-translational modifications (Georgiou and Vakax, 1996; Makrides, 1996; 
Hanning and Makrides, 1998, Jenkins, 2007; Gräslund et al., 2008; Ferrer-Miralles et al., 2009). 
One of the stumbling blocks when using E. coli as an expression system is the accumulation of 
endotoxins (also known as lipolysaccharide-LPS) which are harmful to mammals (Terpe, 2006). 
In order for the proteins to become endotoxin-free, a second purification is required (Petsch and 
Anspach, 2000, Terpe, 2006). Another problem is the misfolding of mammalian proteins due to 
prosthetic groups, disulfide bonds and multiple subunits (Georgiou and Valax, 1996).  This is 
one of the reasons why antibodies lacking glycosylation, are not recognised by mammals 
(Jenkins and Curling, 1994). Protein degradation is also another problem due to the presence of 
proteases present in the outer and inner membranes, the cytoplasm and the periplasm 
(Goldberg and Goff, 1986; Baneyx and Georgiou, 1992; Goldberg, 1992; Gottesman and 
Maurizi, 1992; Maurizi, 1992; Makrides, 1996).  
 
E coli is used for the production of products such as hormones, interferons and interleukins 
(Ferrer-Miralles et al., 2009).  These proteins produced by E. coli are important in the treatment 
of several disorders (metabolic, nutritional and endocrine) and infectious diseases (Ferrer-
Miralles et al., 2009).  According to results reported by Roman et al. (1995), more than 20 
mg.ml-1 of active rat neuronal nitric oxide synthase (nNOS) was produced by E. coli as opposed 
to less than 1 mg.ml-1 by recombinant human kidney cells.  E. coli was also used, along with the 
fungus Aspergillus niger, to recombinantly produce mammalian chymosin and this was 
approved in USA (Cowan, 1996).  In comparison to natural calf chymosin, the price of the 
recombinant produced chymosin decreased by half (Cowan, 1996). 
 
 
There are other bacterial expression hosts that are commonly used for heterologous protein 
production such as the gram positive Bacillus species. There are several pharmaceutical 
peptides that have been expressed by Bacillus strains (Table 1). One of the advantages of 
using Bacillus strains as opposed to E. coli stains is that they have the ability to naturally 
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secrete proteins into the extracellular medium and the outer membrane does not contain 
endotoxins (Terpe, 2006). Several proteins that have been expressed are enzymes, hormones 
and antibodies. Udaka and Yamagata (1993) managed to express 3000 mg.l-1 of α-amylase 
from B. stearothermophilus using B. brevis as an expression system (Terpe, 2006).  
 
Others strains include B. subtilis used by Olmos-Soto and Contreras-Flores (2003) to produce 
1000 mg.l-1 of Proinsulin and B. megaterium used to produce 362 U.g-1 of Dextransucrase from 
Leuconostoc mesenteroides (Malten et al., 2005; Terpe, 2006).  The use of bacteria as 
expression systems play a vital role in recombinant protein production especially ones that don’t 
require glycosylation but it ultimately depends on the properties of the protein of interest (Verma 
et al., 1998).   
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Table 1: List of some the proteins heterologously produced by Bacilli strains (adapted from Terpe, 2006). 
Bacillus strain Recombinant protein  Reference 
B. brevis Epidermal growth hormone (human) Yamagata et al., 1989 
 α-amylase (human) Konishi et al., 1990 
 Cholera toxin B Ichikawa et al.,1993 
 α-amylase (Bacillus stearothermophilus) Udaka and Yamagata, 1993 
 Pepsinogen (swine) Udaka and Yamagata, 1993 
 Epidermal growth hormone (mouse) Wang et al., 1993 
 Mouse/human chimeric Fabʹ Inoue et al., 1997 
 Interleukin-2 (human) Takimura et al., 1997 
 Protein disulfide isomerase  Kajino et al., 1999 
 Gelatin Kajino et al., 2000 
 Interleukin-6 (human) Shiga et al., 2000 
 Cellulase Kashima and Udaka, 2004 
B. subtilis α-amylase (Bacillus amyloliquefaciens) Palva, 1982 
 Interferon-α2 (human) Palva et al., 1983 
 Lipase A Lesuisse et al., 1993 
 Epidermal growth hormone (human) Lam et al., 1998 
 Staphylokinase Ye et al., 1999 
 Penicillin G acylase Yang et al., 2001 
 PHA depolymerase A (Paucimonas 
lemoignei) 
Braaz et al., 2002 
 ScFv Wu et al., 2002 
 Streptavidin Wu and Wong, 2002 
 Thioredoxin (Aliciclobacillus acidocaldarius) Anna et al., 2003 
 Proinsulin Olmos-Soto and Contreras-
Flores, 2003 
B. megaterium Dextransucrase (Leuconostoc 
mesenteroides) 
Malten et al., 2005 
 Toxin A (Clostridium difficile) Burger et al., 2003 
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2.5 Plant expression systems 
 
During the past two decades, plant based expression systems have been used for heterologous 
protein production. The first production of an antibody using a plant based expression system 
occurred in 1989 and the first recombinant hormone produced was human growth hormone 
using the tobacco plant (Hiatt et al., 1989; Staub et al., 2000). Several therapeutic drugs, 
recombinantly expressed in plants, are currently in clinical trials. Two in particular: IgA used for 
tooth decay (CaroRxTM- from Planet Biotechnology Inc, Ma et al., 1998, Ma et al., 2005) and a 
human intrinsic factor used for the treatment of vitamin B12 deficiency (Cobento Biotech AS) 
has been approved for consumption by humans (Faye and Gormord, 2010).  Ventria Bioscience 
(http://www.ventria.com) has been genetically modifying field grown rice for the heterologous 
production of human lactoferrin and human lysozyme (Zavaleta et al., 2007; Huang et al., 2008; 
Faye and Gormord, 2010). 
 
SemBioSys Genetics Inc (http:// www.sembiosys.com/) had one of its products, recombinant 
insulin produced in safflower plant seeds, enter phase III of clinical trials (Boothe et al., 2010). 
The American Food and Drug Administration (FDA) have approved vaccines, made by plants, 
used in the treatment of non-Hodgkin’s lymphoma (McCormick et al., 2008).  Plant cells have 
proven to be alternative systems for biopharmaceutical production including the approved 
vaccine by the USDA Center for Veterinary Biologics produced in tobacco suspension-cultured 
cells by a company called Dow Agroscience for chickens against the Newcastle disease virus   
and genetically engineered carrot cells for the production of human glucocerebrosidase against 
Gaucher’s disease (Faye and Gormord, 2010; Shaaltiel et al., 2007).  
 
Plants have the advantages of low cost cultivation, lack of human pathogens and high cell mass 
production (Ferrer-Miralles et al., 2009) however using plant expression systems can also be 
time-consuming as they grow slowly. Although plant expression systems can produce 
recombinant peptides at a lower cost, free from bacterial contaminants and human viruses, 
many pharmaceutical industries are reluctant to use them (Faye and Gormord, 2010).  One of 
the major problems encountered by plant expression systems is that its post-translational 
modification mechanisms sometimes produces recombinant proteins that have an adverse 
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immune response in mammals (Ferrer-Miralles et al., 2009).  Mammalian expression systems 
are commonly used for expression of mammalian proteins that require a higher level of post-
translational modification.  
 
2.6 Mammalian expression systems 
 
Mammalian cells are most commonly used for producing recombinant mammalian glycosylated 
proteins (Demain and Vaishnav, 2009). Genetically Modified Animals are commonly used to 
secrete recombinant proteins in their milk, blood or urine (Demain and Vaishnav., 2009). 
Currently only ATryn has been approved using transgenic animals and this was secreted in 
goat’s milk. (Ferrer-Miralles et al., 2009). Mammalian cell systems, CHO (Chinese hamster 
ovary cells) and hybridoma cells, are most similar to human cells therefore allowing recombinant 
expression of correctly folded and glycosylated proteins which are readily recognised by 
mammalian cells (Verma et al., 1998, Martínez et al., 2012). CHO cells grow in medium that is 
chemically defined, serum and protein free (Bleckwenn and Shiloach, 2004). Post translational 
modification are similar to human cells when using CHO cells as expression systems but it was 
established that glycosylation patterns differed between different batches of the same 
recombinant protein (Yuen et al., 2003; Ferrer-Miralles et al., 2009).  The FDA approved two 
products: Xyntha and Recothrom produced using CHO cells (Ferrer-Miralles et al., 2009). Other 
expression systems include human cell lines which have been used to express approved 
therapeutic proteins such as Dynepoerithropoietin, Replagal-alfa-galactosidase A and elaprase-
irundonate-2-sulfatase (Ferrer-Miralles et al., 2009). 
 
However, one needs to consider the disadvantages when using mammalian expressing 
systems for recombinant gene protein production. These include the high cultivation costs 
associated with growth medium such as costly growth factors and the high risk of 
contamination, limited secretion capacity and low protein yields (Demain and Vaishnav, 2009; 
Martínez et al., 2012). Yeast expression systems offer the advantage of producing glycosylated 
proteins using minimal, inexpensive medium.   
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2.7 Yeast expression systems 
 
Several yeast expression systems have acquired GRAS status by the FDA as opposed to 
several prokaryotic organisms that may contain endotoxins and mammalian cells with the 
possibility of viral DNA contamination (Domínguez et al., 1998). They offer numerous 
advantages for the expression of complex proteins in that they retain the easiness of bacterial 
manipulation and growth characteristics (Madzak et al., 2004). Being unicellular, they also 
“possess an eukaryotic subcellular organisation able to perform the post-translational 
processing of complex proteins” (Madzak et al., 2004).  In comparison to E. coli, yeast 
expression systems have the capability to secrete correctly folded proteins (Verma et al., 1998). 
Yeast expression systems also have the ability to reach high cell densities in bioreactors and 
are faster and cheaper to manipulate as opposed to animal and plant expression hosts (Ferrer-
Miralles et al., 2009; Martínez et al., 2012). 
 
Yeast cells are less sensitive to contamination due to their cell walls being resistant to shear 
stress during protein production and have the ability to grow in media that is not costly as 
compared to mammalian cells (Verma et al. 1998; De Pourcq., 2010; Martínez et al., 2012). 
During fermentation, protein production can reach more than 1 g.l-1 in a matter of days as 
compared to other expression systems (Gerngross., 2004). The production of hirudin, a 
thrombin inhibitor was compared using different expression systems (Table 2) by Demain and 
Vaishnav (2009). Yeast showed the highest production of the recombinant protein. 
 
Table 2: Comparison of hirudin production using different expression systems (adapted from Demain and 
Vaishnav, 2009). 
Recombinant hosts Organism mg.l
-1
 
BHK cells Mammalian 0.05 
Insect cells Insect 0.40 
Streptomyces lividans  Bacterial 0.25-0.5 
Escherichia coli Bacterial 200-300 
Saccharomyces cervisiae Yeast 40-500 
Hansenula polymorpha Yeast 1500 
Pichia pastoris Yeast 1500 
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Saccharomyces cerevisiae is the most commonly used yeast for heterologous protein 
production in the past. Vast amounts of knowledge are widely available for this host.  It has 
been used as an expression system for several proteins such as 0.09 g.l-1 of human serum 
albumin (Okabayashi et al., 1991), 1 g.l-1 of Tetanus toxin fragment C (Romanos et al., 1991) 
and 9 g.l-1 of glucose oxidase from Aspergillus niger (Park et al., 2000; Adrio and Demain, 2010) 
to name a few. 
 
S. cerevisiae, however, has several limitations: “low product yield, poor plasmid stability, 
difficulties in scaling-up production, hyperglycosylation, and low secretion capacities” (Madzak 
et al., 2004). Due to these limitations of S. cerevisiae, alternative yeast systems have been 
found and these include: the methylotrophs, Picha pastoris and Hansenula polymorpha; the 
dairy yeast, Kluyveromyces lactis; the amylolytic yeast, Schwanniomyces occidentalis and the 
alkaline utilizer, Yarrowia lipolytica (Müller et al., 1998).  
 
P. pastoris is another commonly used yeast expression system that has been exploited over the 
past few decades with high level recombinant production (Cereghino and Gregg., 1999, 
reviewed by Cereghino and Cregg, 2000).  It was developed by the Phillips Petroleum Company 
for the expression of single cell proteins with the potential to achieve more than 130 g.l-1 of dry 
cell weight in a continuous culture and has the ability to grow on methanol as an only source of 
energy (Ogata et al., 1969; Wegner, 1990; Domínguez et al., 1998). P. pastoris has been used 
in the production of 10 g.l-1 of human serum albumin (Kobayashi et al., 2000), 12 g.l-1 of Tetanus 
toxin fragment C (Clare et al., 1991) and 14.8 g.l-1 of Gelatin (Werten et al., 1999) to name a 
few. As an expression system, its production yields are much higher than S. cerevisiae when 
expressing the same proteins (111 fold higher for HSA and 12 fold higher for Tetanus toxin 
fragment C).  
 
Another expression host, that has been described as one of the most attractive non 
conventional yeast host strains for recombinant protein expression is Yarrowia lipolytica (Müller 
et al., 1998). During the mid-1960s, the production for single-cell proteins emerged. Y. lipolytica 
was able to arouse a strong industrial interest because of its capability to grow on n-paraffins. 
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This substrate could be used as an only carbon source and was very cheap and plentiful during 
this period. (Barth and Gaillardin., 1997).   
 
2.8 Yarrowia lipolytica 
 
Y. lipolytica ascomycetous yeast was previous classified as Candida, Endomycopis and 
Saccharomyces lipolytica (Barth and Gaillardin., 1997). It was first discovered by Wickerham in 
1945 after isolation from a jar that contained fibre tailings from a corn processing plant which 
was found to form hyphal elements attached to asci when a certain type of medium was used 
(Barth and Gaillardin, 1997). It has been used in many industrial applications many of which 
have been classified as safe by the FDA. These include the production of citric acid, peach 
flavour and peptides (Nicaud et al., 2002).  
 
This dimorphic yeast has the capacity to secrete several recombinant proteins efficiently  
withseveral molecular tools available for post-translational modification (Madzak et al., 
2004;Pignede et al., 1998; Lopes et al., 2008). Y. lipolytica has been classified as non 
pathogenic (Holzschu et al., 1979) with the ability to naturally secrete several enzymes including 
lipases, RNAses, proteases and esterases (Barth and Gaillardin., 1997). In comparison to other 
well-known yeasts such as S. cerevisiae  and Schizosaccharomyces pombe, Y. lipolytica is able 
to ultilize several substrates: alkanes, fatty acids, glucose and organic acids (Barth and 
Gaillardin , 1997). In the past, Y. lipolytica was used to produce high amounts of organic acids 
by growing on n-paraffins (Tsugawa et al., 1969). This allowed for upscaling of products with the 
accumulation of large amounts of datafor fermentation processes. (Barth and Gaillardin., 
1997).This organism can produce between 1-2 g.l-1alkaline extracellular protease (AEP) when 
grown on YPD medium (Tobe et al., 1976, Ogrydziak and Scharf, 1982; Barth and Gaillardin, 
1997). 
 
Lip2 is a native enzyme expressed by Y. lipolytica at high concentrations (Pignede et al., 2000a; 
Pignede et al; 2000b; Fickers et al., 2005) and hence was used as a fusion partner for 
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expression of a galactose oxidase M1 enzyme, a camelid antibody fragment and a trypsin 
inhibitor (Hofmeyer et al., 2013).  
 
There are several Y. lipolytica strains available for heterologous gene expression. These include 
the Pold strain deleted for an alkaline extracellular protease by Le Dall et al., (1994) with the 
ability to utilise the carbon source sucrose (Nicaud et al., 1989) and the Po1f, Po1g and Po1h 
strains (Madzak et al., 2000; Madzak, 2003) deleted for both extracellular proteases (acid and 
alkaline). Polf and Polh strains were used for integration of yeast expression cassettes from 
auto-cloning vectors (Madzak et al., 2000; Madzak., 2003). Po1g and Po1h retained one 
auxotrophic marker with Po1g containing an extra pBR322 docking integration platform (Madzak 
et al., 2000; Madzak., 2003). The most commonly used selection markers are LEU2 and URA3 
(Le Dall et al., 1994; Madzak et al., 2004). 
 
There are several plasmids that exist and are designed specific for host strains with selection 
markers. The pINA1296 plasmid was designed by Madzak et al., (2000) for integration at the 
pBR322 docking platform of the Polg strain of Y. lipolytica. The pINA1297 vector was designed 
as a “zeta based auto-cloning multi copy vector” for integration into the Po1f and Po1h strains 
(Nicaud et al., 2002; Madzak et al., 2004). The integrative pKOV410 plasmid is commonly used 
by the CSIR (Bulani et al., 2012; Hofmeyer et al., 2014) (which was kindly donated by the 
University of the Free State) was used for the purpose of this study (Figure 6).  
 




Figure 6: The pKOV410 plasmid containing the Lip2-Exe fusion gene was randomly integrated into the 
genome of Y. lipolytica. 
 
This plasmid was transformed to contain expression cassette: which consisted of a lipase gene 
(Lip2), 6 x histidine (His) tag, an enterokinase cleavage site (ECS) and the exenatide (Exe) 
peptide (39 amino acids) with the addition of a glycine residue to the C-terminal end (necessary 
for downstream processing – amidation) (Figure 6). The plasmid contained the sequence that 
targets the rDNA location of the strain YlEx-gly and a LEU2 auxotrophic marker. 
 
Apart from choosing the most appropriate plasmid for gene expression, finding the correct 
promoter for optimal expression is crucial. According to Müller et al. (1998), a promoter that is 
tightly regulated allows one to separate the growth and expression stages hence allowing 
protein expression which can inhibit cell growth. When choosing the appropriate promoter for 
expression, the following needs to be considered: it must be strong, capable of producing 
between 10- 30% of a recombinant protein in excess of the total protein produced by the 
organism, it should show a low level of basal transcription during growth of the organism 
especially for toxic proteins and induction should be cost-effective and simple (Hannig and 
Makrides, 1998). There are a variety of promoters available for heterologous gene expression 
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The XPR2 promoter is the most commonly used promoter for recombinant protein production by 
Y. lipolytica. It is only active at pH’s above 6 in medium that doesn’t contain carbon and nitrogen 
and induction requires high levels of peptone (Ogrydziak et al., 1977; Ogrydziak and Scharf, 
1982, Franke et al., 1988). The RPS7 and TEF promoters were isolated by Müller et al. (1998) 
and have been described as constitutive and strong. The downfall of having a constitutive 
promoter is that early protein production could affect the growth of the organism (Madzak et al., 
2004). Other promoters that were isolated by Madzak et al. (2004) include the POX promoters 
(acyl-CoA oxidases POX1, POX2 and the POX5 ), the POT1 promoter (3-oxo-acyl-CoA 
thiolase) and ICL1 (isocitrate lyase). These promoters were studied against the XPR2, the hp4d 
and the G3P (glycerol-3-phosphate dehydrogenase) promoters by monitoring their regulatory 
mechanism during growth of Y. lipolytica (Juretzek et al., 2000; Madzak et al., 2004). The 
outcomes yield that POT1 and POX2 was repressed by the carbon sources glycerol and 
glucose and induced by alkanes and fatty acids, ICL1 was induced by acetate, alkanes, fatty 
acids and ethanol although not completely repressed by glycerol and glucose (Juretzek et al., 
2000; Madzak et al., 2004).  
 
The XPR2 promoter was critically analysed by Blanchin-Roland et al., 1994 and Madzak et al., 
1999). It was found that an upstream activating sequence, designated as UAS1, was not 
affected significantly by environmental conditions. This sequence was used to design a 
recombinant promoter called hp4d that was not affected by medium composition such as 
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nitrogen and carbon sources or pH or peptones (Madzak et al., 1995; Madzak et al., 2000). It 
was said to drive a strong gene expression and its regulation to be  growth phase dependent 
starting at early stationary phase (Madzak et al., 2000; Nicaud et al., 2002). This promoter has 
been used for the recombinant production of several proteins such as epoxide hydrolase from 
Rhodotorula araucariae, endo-ß-1, 4-mannanase from Aspergillus aculeatus, a galactose 
oxidase M1 enzyme, a camelid antibody fragment and a trypsin inhibitor (Maharajh et al., 2008; 
Roth et al., 2009, Hofmeyer et al., 2014; Madzak et al., 2004).  
 
2.9 Concluding Remarks 
 
The CSIR is developing a process for the recombinant production of pharmaceuticals peptides 
in Y. lipolytica. The production of lipase (Lip2), under regulation of the hp4d promoter was 
previously elucidated in continuous fermentation and found to be linked to growth rate with high 
production yields occurring at growth rates lower than 0.045 h-1 (van Zyl, 2013). However it is 
unclear if this regulation is at the level of transcription or cellular metabolism. Therefore to 
achieve maximum production of pharmaceutical peptides and proteins, the regulation of the 
hp4d promoter needed to be established. A Y. lipolytica stain expressing a fused Lipase and 
Exenatide (Lip2:Exe) precursor, under regulation of the hp4d promoter, was generated (Chapter 
3). The growth and production profiles will therefore be established and compared to literature in 
Chapter 3. An optimised mRNA transcription methodology will be developed and validated in 
Chapter 4 followed by the evaluation of the effect of growth rate on the recombinant production 
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Exenatide (Byetta®) is a type 2 diabetic drug that was discovered by Dr John Eng in the early 
nineties (Mueller, 2007). He isolated a compound from the saliva of the Gila monster after he 
noticed that the endangered lizard's poison stimulated the body's production of insulin, a 
hormone that helps cells decrease blood glucose levels (Somers, 2005). The compound also 
prevented the blood-glucose levels from dropping dangerously low and stopped it from spiking 
hence preventing damage to the eyes, liver and kidneys (Somers, 2005). It was later licensed 
by Amylin Pharmaceuticals and marketed as the diabetic drug Byetta® and therefore is used as 
an alternative to insulin for the treatment of type 2 diabetes (Mueller, 2007; Kyriacou and 
Ahmed, 2010). The cost of treatment using this drug is very expensive. On average, it costs 
approximately $ 1800 for 5 µg and $ 2200 for the 10 µg dosages annually per patient per year 
(Bond, 2006). The main reason for the high treatment costs is due to several steps required 
during the manufacturing process (chemical synthesis) of the drug. A potential cost-effective 
alternative using recombinant protein expression exists and with Y. lipolytica as a host. 
  
A Y. lipolytica Po1f strain, expressing the fused Lip2:Exe precursor, was generated by Dr 
Ramagoma1 and Dr Bulani2  from the Biosciences Department at the CSIR (Table 4) and kindly 
donated for the purpose of this study. The integration plasmid pKOV410 (kindly donated by the 
University of the Free State) was used which contained the sequence that targets the rDNA 
location of the strain YlEx-gly, the expression cassette: which consisted of a lipase gene (Lip2), 
6 x histidine (His) tag, an enterokinase cleavage site (ECS) and the exenatide (Exe) peptide 
(39 amino acids) with the addition of a glycine residue to the C-terminal end (necessary for 
downstream processing – amidation) (Figure 7) and a LEU2 auxotrophic marker.  
                                               
1
Dr Faranani Ramagoma, CSIR Biosciences, P. O. Box 395, Pretoria, South Africa 
2
Dr Siyavuya Ishmael Bulani, CSIR Biosciences, P. O. Box 395, Pretoria, South Africa 
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Table 4: Genotypes of Y. lipolytica strain containing the Lip2:Exe fusion peptide. 
 Characteristics Reference 
Strain   
Y. lipolytica Po1f 
 
∆MatA, ∆leu2-270, ∆ura3-302, 
∆xpr2-322, ∆axp-2 
(Madzak et al., 2000) 
 








Figure 7: The Lip2:Exe expression cassette integrated into the genome of Y. lipolytica. 
 
3.2 Materials and Methods 
 
3.2.1 Cell banking of Y. lipolytica (YlEx-gly) expressing the fused Lip2:Exe 
precursor  
 
Ultra Yield (2.5 l, Biosilta®, United Kingdom) flasks (n = 5), containing sterile (autoclaved at 121 
°C for 20 min) YPD (100 ml) medium [1 % yeast extract (m.v-1, Merck, Germany), 1 % peptone 
(m.v-1, Merck, Germany) and 2 % glucose (m.v-1, Merck Millipore, Germany), pH 6.4], were 
inoculated by transferring a single colony of Y. lipolytica (Ylex-gly) from a plate counting agar 
(PCA) plate (stored at 4°C for 1 week). These plates containing the YlEx-Gly strain were 
donated by Dr Bulani and Dr Ramagoma. The flasks were incubated on an orbital shaker (180 
rpm) at 28°C and aseptically sampled (2 ml) every 2 h. The growth of the organism was 
followed by measuring the optical density (OD) at 660 nm using a Beckman Coulter DU800 
spectrophotometer (Beckman Coulter, USA). When mid-exponential phase (OD: 4–7) was 
reached, all flasks were microscopically checked for monoculture and  pooled together followed 
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by cryopreservation of organism by mixing cold sterile glycerol (4°C, 50 % m.v-1) with culture 
broth at a ratio of 1:1 followed by aseptically dispensing 2 ml aliquots into sterile cryo-vials (2 
ml). The cryo-vials were thereafter placed in Nalgene cryo-containers containing 250 ml 
Isopropyl Alcohol (IPA) and stored at -80°C. After a period of 48 h, the cryo-vials were 
transferred to storage cryo-boxes and stored at -80°C. This was followed by growth curves and 
validation studies of the cell bank. 
 
3.2.2 Growth curve study and validation of the cell bank for production of 
the fused Lip2:Exe precursor  
 
Ultra yield (2.5 l) flasks (Biosilta®, United Kingdom) containing sterilised (autoclaved at 121°C 
for 20 min) YPD (700 ml, pH 6.4) medium were inoculated with cryo-vials (one cryo-vial per 
flask) from the cell bank (n = 5). The flasks were incubated on an orbital shaker (180 rpm) at 
28°C and growth profiles were established by aseptically removing culture broth every 2 h and 
measuring OD660nm, pH, biomass production (section 3.2.4.1) and residual glucose 
concentration (Accutrend®, Germany) for the first 26 h. The growth rate (Equation 1) and 
doubling time (Equation 2) for Y. lipolytica were established using the following formulas: 
 
Growth rate (µ) = 2.303 x (log10 OD2 – log10 OD1) / (Time2 – Time1)        Equation 1 
Doubling time (tD) = ln 2 / µ             Equation 2 
 
Following the growth curve study, the cell bank was validated for production of the fused 
Lip2:Exe precursor by Y. lipolytica (YlEx-gly). Ultra yield (2.5 l) flasks containing sterilised 
(autoclaved at 121°Cfor 20 min) YPD (700 ml, pH 6.4) medium were inoculated using YlEx-gly 
containing cryo-vials (one cryo-vial per flask) from the cell bank (n = 5). The flasks were 
incubated on an orbital shaker (180 rpm) at 28°C. Samples (10 ml) of culture broth were 
aseptically removed from each flask, at regular intervals, to measure pH, residual glucose 
concentration, biomass production (section 3.2.4.1) and OD660nm followed by centrifugation of 2 
ml samples (n = 3) at 13000 x g for 10 min. The supernatant was dispensed into sterile 
Eppendorf tubes and stored at -20°C for quantification of total extracellular protein and lipase 
production (sections 3.2.4.2 and 3.2.4.3 respectively). 




3.2.3 Batch fermentation of Y. lipolytica 
 
Upon validation of the cell bank using a flask trial, batch fermentation was used to scale-up 
production of the fused Lip2:Exe precursor. Labfors 3 fermenters (Infors HT, Switzerland) with a 
1.7 l working volume (n = 4), were initially pressure tested for any leaks followed by calibration 
of pH and DO (Dissolved Oxygen) probes. YPD medium (1.2 l, pH 6.8) was prepared in each 
fermenter and autoclaved at 121°C for 45 min. Once the temperature of the medium had 
reached 25°C, each fermenter was inoculated with a 2 ml cryo-vial, containing Y. lipolytica 
(YlEx-gly) expressing the fused Lip2:Exe precursor using a 2 ml cyro-vial from the cell bank.  A 
sterile syringe was used to inject the inoculums via the septated port. The temperature was 
controlled at 28°C and the aeration was set to 1 slpm (standard liters per minute).  The starting 
agitation was set at 300 rpm and ramped to 1000 rpm in order to maintain the pO2 (dissolved 
oxygen) at 30 % saturation. Samples (20 ml) of culture broth were aseptically removed, at 
regular intervals, to measure pH, residual glucose concentration, biomass production (section 
3.2.4.1) and OD660nm. Triplicate samples (2 ml) were centrifuged at 13000 x g for 10 min and the 
supernatant was dispensed into sterile Eppendorf tubes and stored at -20°C for quantification of 
total extracellular protein and lipase production (sections 3.2.4.2 and 3.2.4.3 respectively). The 
supernatant was also used to observe extracellular protein production by running SDS PAGE 
gel electrophoresis (section 3.2.4.4). The fermentation culture broth was microscopically 
checked on a daily basis to ensure monoculture status. 
 
3.2.4 Analysis used for study 
 
3.2.4.1 Biomass production determination 
 
Biomass (Dry Cell Weight) production was quantified by centrifuging 2 ml samples at 13000 x g 
for 10 min in pre-weighed (Weight 1) Eppendorf tubes (2 ml). The supernatant was discarded 
and the pellet left to dry at 110°C until constant weight was reached (Weight 2). Each tube was 
weighed and the biomass calculated using Equation 3. 




Biomass (g.l-1) = (Weight 2 – Weight 1) x 500          Equation 3 
 
3.2.4.2 Protein concentration determination assay 
 
The Bradford (Bradford, 1976) assay method uses the dye-binding principle, giving off a colour 
change, depending on the concentration of total extracellular protein. A BSA (Bovine Serum 
Albumin; Roche, Germany) standard curve was generated prior to quantification at a 
concentration range of 0.0 - 0.5 mg.ml-1.  
 
Bio-Rad (Bio-RadTM, USA) protein assay reagent (200 µl) was added to 10 µl of sample (n = 4) 
in a 96 well flat-bottom microtiter plate (samples were diluted to fit within the standard curve). 
The plate was left shaking (200 rpm) for 5 min at room temperature to ensure efficient binding of 
the dye to the protein. The end point reaction was quantified at 595 nm (BioTek PowerWaveTM 
HT, USA) and read against a BSA standard curve in order to determine the total extracellular 
protein concentration of each sample. All assays done were done in quadruplicate. 
 
3.2.4.3 Lipase kinetic assay 
 
Lipase (Lip2) was used as a reporter enzyme to give an indication of the amount of fused 
Lip2:Exe produced. The lipase assay (Vorderwülbecke et al., 1992) measured the release of 
ρ-nitrophenol during cleavage of the substrate ρ-nitrophenylpalmitate by the Lip2 enzyme. 
Solutions A and B were prepared according to Table 5. 
 
Table 5: Lipase Assay components used to quantity the amount of fused Lip2:Exe produced. 
Solution Component Concentration  
A ρ-Nitrophenylpalmitate 3.0 mg.ml
-1
 
 Propan-2-ol 1.0 ml.ml
-1
 
B Tris-HCI buffer (50 mM, pH 8.0) 1.0 ml.ml
-1
 
 Na-deoxycholate 4.4 mg.ml
-1
 
 Gum arabic 1.1 mg.ml
-1
 




Solution A was added drop-wise to solution B at a ratio of 1:9 whilst stirring (200 rpm, 37°C) 
using a heating-stirrer plate. The reaction was initiated by the addition of 240 µl of the combined 
solution (37°C) to 10 µl of enzyme sample (supernatant) in a 96 well flat-bottom microtiter plate. 
All assays done were done in quadruplicate. The release of ρ-nitrophenol was monitored at 410 
nm (37°C) using a microtiter plate reader (BioTek PowerWaveTM HT, USA). The activity of the 
enzyme was calculated as U.ml-1 using Equation 4: 
U.ml-1= (V /v x Є x d) X A/min            Equation 4 
Where by:  
V = final volume,  
v = sample volume,  
Є = Extinction coefficient of ρ-nitrophenol at 410 nm (pH 8.0)  
   = 15 (1 x nmol-1 x cm-1 = ml x µmol-1 x cm-1),  
d = light path of cuvette, 
A.min-1 = change of absorbance per minute.  
The U.ml-1 was converted to nKat.ml-1 by multiplying with a constant of 16.8. 
 
3.2.4.4  SDS PAGE gel electrophoresis to monitor extracellular protein 
production 
 
In order to observe extracellular protein production, SDS PAGE gel electrophoresis was used 
(Laemmli., 1970). Supernatant (10 µl) was combined with 10 µl of sample buffer (62.5 mM Tris-
HCl, pH 6.8, 20 % Glycerol, 2 % SDS, 5% β-Mercaptoethanol) followed by 10 min incubation at  
95°C, on a heating blocking. The tubes were briefly centrifuged for 5 sec to ensure even mixing 
of the sample and buffer. The samples (10 µl) were loaded onto a 12% SDS-PAGE gel 
[separating gel consisted of: 30 % Bis/Acrylamide (Sigma-Aldrich, USA), 1.5 M Tris- HCl, pH 
8.8, 10 % (w/v) SDS, 10 % (w/v) Ammonium Persulfate (Sigma-Aldrich, USA) and TEMED 
(Sigma-Aldrich, USA);  stacking gel consisted of: 30 % Bis/Acrylamide (Sigma-Aldrich, USA), 
0.5 M Tris- HCl, pH 6.8, 10 % (w/v) SDS, 10 % (w/v) Ammonium Persulfate (Sigma-Aldrich, 
USA) and TEMED (Sigma-Aldrich, USA)] and electrophoresed (running buffer: 25 mM Tris, 192 
mM glycine and 0.1 % (w/v) SDS, pH 8.3) through the stacking gel at 100 V for 20 min followed 
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by 200 V for 30 min for the seperating gel. The molecular weight marker that was used as a 
reference is the SpectraTM Multicolor Broad Range Protein Ladder (Thermo Scientific USA). The 
SDS gel was stained using the Colloidal Coomassie Blue Staining method (Kang et al., 2002; 
Neuhoff et al., 1988). 
 
3.3 Results and Discussion 
 
A cell bank was generated for Y. lipolytica (YlEx-gly) expressing the fused Lip2:Exe precursor. 
The glycerol stocks were checked for a monoculture followed by the evaluation of growth curve 
profiles and validation of recombinant production of the fused Lip2:Exe precursor.  
 
3.3.1  Y. lipolytica (YlEx-gly) growth profile characteristics and 
recombinant production of the fused Lip2:Exe precursor 
 
The cell bank for Y. lipolytica (YlEx-gly) was generated and confirmation of a monoculture 
present in the glycerol stocks was microscopically checked (Figure 8) and then streaked (10 µl) 
onto PCA plates. Growth was followed by measuring the OD660nm and biomass (section 3.2.4.1) 
for 26 h (Figure 9A).  
 
Figure 8: Confirmation of monoseptic culture. The glycerol stocks were visualised, at 100 x magnification, 
for the presence of Y. lipolytica cells using a light mircoscope. 
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When using glucose as a substrate, the decrease in pH is due to the production of organic acids 
(such as citric acid) and the increase in pH due to proteolysis and the reutilization of organic 
acids after glucose depletion (Revah and Lebeault., 1989; Rane and Sims., 1996; Papanikolaou 
et al., 2002). Lipase was detected after 24 h (Figure 10B).  A maximum lipase activity of 
1287(± 81.40 nKat.ml-1) was observed at 50 h, 10 h after glucose depletion, followed by a rapid 
decrease to 319(± 46.30) nKat.ml-1 at 126 h.   
 
The total extracellular protein concentration increased from 0.916(± 0.08) g.l-1 at 75 h to 1.34(± 
0.08) g.l-1 at 126 h. This was 7.7 fold higher than Hofmeyer et al. (2014) who achieved up to 174 
mg.l-1 of fused protein during shake flask studies. Following the validation of the cell bank using 
a flask trial, batch fermentation was used to further upscale the production of the fused Lip2:Exe 
precursor peptide. 
 
3.3.2 Batch fermentation of Y. lipolytica 
 
Batch fermentation was used to validate the cell bank for production of the fused Lip2:Exe 
precursor at a 1.2 l scale. The maximum growth rate during the exponential phase was 0.346 h-1 
with a doubling time of 2.89 h. The maximum OD660nm of 26.1 and biomass of 18.33(± 0.54) g.l
-1 
was reached after 38 h when glucose in the medium was depleted (Figure 11A). The maximum 
volumetric lipase activity of 14042.32(±1008.95) nkat.ml-1 was reached after glucose depletion 
with an overall productivity of 379.52 nkat.ml-1.h-1. A 10.91 fold higher production in lipase 
activity was observed in batch fermentation as opposed to flask studies (Figure 11B). Although 
the lipase productivity decreased after 37 h (explained in Figure 12), protein production 
remained constant and reached a maximum of 0.34 mg.l-1 after 47 h. However, it is unclear if 
Lip2:Exe transcription, under regulation of the hp4d promoter, started at the beginning of the 
exponential growth phase and was only translated at early stationary phase or if Lip2:Exe 
transcription only started at the early stationary phase.  
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concentration as observed in Figures 10B, 11B and 12. Similar lipase profiles have been 
observed by several authors (Lopes et al., 2008; Alonso et al., 2005; Domínguez et al., 2003; 
Corzo and Revah., 1999).    
 
 
Figure 12: Total extracellular protein production profile by Y. lipolytica (YlEx-gly).  
 
3.4 Concluding Remarks 
 
The Y. lipolytica strain expressing the fused Lip2:Exe precursor was cell banked and validated 
for the production of the recombinant protein using flask and batch fermentation studies. It was 
observed that production, under regulation of the hp4d promoter, only started in early stationary 
phase. In order to fully understand the regulatory mechanism of the hp4d promoter, the 
transcription of Lip2:Exe gene fusion needed to be quantified during growth of Y. lipolytica. 
Before this could be done, a methodology to monitor transcripts needed to be optimised and 
validated for reproducibility. This will be undertaken in Chapter 4 prior to the determination of 
the regulation of the hp4d promoter in Chapter 5. 
 








Chapter 4: Optimisation of a 
mRNA sandwich hybridisation 
methodology for Lip2:Exe 
transcript quantification 
 





Transcription of the gene is the first step in the expression of a product and this is initiated by a 
promoter. The regulation of a promoter can be due to several factors such as growth rate, 
growth phase and the presence of substrates (eg. fatty acids, peptones, amino acids, etc.). By 
the measuring the amount of transcripts (mRNA) of a particular gene, one can determine the 
regulatory mechanism of a promoter. This therefore will aid in determining the regulation of the 
hp4d promoter by quantifying the amount of Lip2:Exe mRNA transcripts produced during growth 
of Y.lipolytica YlEx-Gly. 
 
The evolution of transcription monitoring methodologies and development has increased 
overtime.  Many assays have provided the high-throughput monitoring of the mRNA transcripts 
which are based on high specificity and sensitivity (Bustin, 2002). There are several 
methodologies that are currently available to quantify mRNA transcripts under regulation of a 
promoter such as northern hybridization and reverse transcription (RT) PCR. The 
disadvantages of using these protocols are that northern hybridization: is time consuming, 
displays low sensitivity, its quantification potential is limited and RT-PCR requires RNA of high 
quality which does not contain any DNA contaminants and therefore can be costly (Thieme et 
al., 2008).  
 
A fast, reliable methodology was described by Rautio et al. (2003) specific for the quantification 
of mRNA transcripts produced during fermentation. In Figure 13, the principles of the assay are 
highlighted using a modified schematic diagram. The sandwich hybridisation assay depends on 
four oligonucleotide probes (the two helper, capture and detection) bind to the target mRNA 
strand. The capture (biotin-labeled) probe binds to the strepavadin magnetic breads, forming a 
stable support for the interaction between the anti-DIG (Digoxigenin)-alkaline phosphatase FAB 
fragments and the detection (DIG-labelled) probe. An AttoPhos® (Promega, Germany) substrate 
(BBTP: 2'-[2-benzothiazoyl]-6'-hydroxybenzothiazole phosphate) is added and this causes a 
reaction to occur. BBTP is cleaved by the alkaline phosphatase yielding inorganic phosphate 
and BBT (2'-[2-benzothiazoyl]-6'-hydroxybenzothiazole) which gives off a yellow fluorescence 
colour. This fluorescence intensity is used to quantify the amount of transcripts produced using 
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a generated standard curve of known concentrations. (Rautio et al., 2003; Resina et al., 2007; 
Thieme  et al., 2008). Before this method could be used, the conditions for the hybridisation 
solution [1] and breakage of Y. lipolytica (YlEx-gly) cells, prior to quantification of transcripts, 




Figure 13: Modified schematic diagram showing mRNA sandwich hybridisation assay (adapted from 
Rautio et al., 2003). [1]: Binding of probes to the mRNA strand using a hybridisation solution, [2]: The 
Lip2:Exe strand-probe complex [1] binds to the streptavidin magnetic beads providing a structural 
support, [3]: The anti-DIG-alkaline phosphatase binds to the DIG labelled probe, [4]: The added substrate 
(BBTP) is cleaved by the conjugated phosphatase yielding an inorganic phosphate and BBT which gives 
off a yellow fluorescent colour that is used to quantify the amount of transcripts (Lip2:Exe) in the sample. 
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4.2 Materials and Methods 
 
4.2.1 Generation of mRNA oligonucleotide probes for sandwich 
hybridization assay 
 
Complementary oligo mRNA Probes (Table 6), specific for the Lip2:Exe mRNA (Figure 14), 
were chosen using the sequencing program Gene Runner (Hastings Software, Inc.)  
 
Table 6: Complementary mRNA probes designed for sandwich hybridization assay. 
 
Probe Sequence Thermodynamic 
values (Tm) 
Helper probe 1 5΄CGTCGTGATGGTGGTGGTGGTGAT 3΄ 60.8 
Dig labelled probe 5΄ CCCTCGCCGTGCTTGTCGTCAT 3΄ 61.4 
Biotinylated probe 5΄ CTGCTTAGACAGGTCAGAGGTGAAGGTG 3΄ 59.1 






Figure 14: Portion of Lip2:Exe sequence indicating the binding positions of four complementary probes. 
The first helper probe binds to the region highlighted in green, the dig-labeled probe to yellow, and the 
biotinylated probe in red followed by the second helper in turquoise. 
 
All probes were synthesized by Inqaba Biotec (South Africa). The detection probe was labeled 
using the DIG Oligonucleotide Tailing Kit, 2nd generation (Roche Diagnostics, Switzerland) as 
per manufacturer’s protocol. Briefly, 100 ρmol of oligonucleotide (detection probe) was added to 
sterile double distilled water (Milli Q) to a final volume of 9 µl in a sterile Eppendorf tube on ice. 
To this reaction tube, 4 µl of a reaction buffer (1 M potassium cacodylate, 0.125 M Tris-HCl, 
Stellenbosch University  https://scholar.sun.ac.za
43 
 
1.25 mg.ml-1 BSA, pH 6.6), 4 µl of a 25 mM CoCl2 solution, 1 µl of a 1 mM DIG-dUTP solution, 1 
µl of a 10 mM dATP solution and 1 µl of a 400 U.µl-1 Terminal transferase solution (prepared in 
60 mM K-phosphate; pH 7.2), 150 mM KCl, 1 mM 2-Mercaptoethanol, 0.5 % (v.v-1) Triton X- 100 
and 50 % (v.v-1) glycerol) was added. The tube was mixed and centrifuged for 5 sec followed by 
incubation for 15 min at 37°C. The reaction was placed on ice and stopped by the addition of 2 
µl 0.2 M EDTA (pH 8). The labelled probe was dispensed into sterile Eppendorf tubes and 
stored at -80°C. The biotin probe was labeled by Inqaba Biotec. 
 
4.2.2 Generation of standards for mRNA sandwich hybridization assay 
 
4.2.2.1 Generation of DNA standard using PCR 
 
Primers were designed (Table 7) to generate copies of a portion of the Lip2:Exe peptide (vector 
kindly donated by Dr. S.I. Bulani3)  using a technique called polymerase chain reaction (PCR). 
The T7 Exe Forward primer was designed to include the T7 promoter sequence (in blue) that 
was necessary for downstream transcription of DNA to RNA using the MAXIscript® Kit (Life 
Technologies, USA) which uses a T7 polymerase. The KAPA 2G PCR kit (Kapa Biosystems, 
South Africa) was used to generate copies of the DNA fragment during PCR (Table 8). Using a 
Thermocycler (Labnet International Inc, USA), all PCR amplifications started with an initial 
denaturing step for 30 sec at 95°C followed by 35 cycles of denaturing for 30 sec at 95°C, 
annealing for 30 sec at 50°C and extension for 45 sec at 72°C. The last step involved 
elongation at 72°C for 2 min. 
 
 
Table 7: Primers used for PCR reaction of Lip2:Exe DNA fragment 
 
Primer Sequence 
T7 Exe Forward 5΄ TAATACGACTCACTATAGGGAGATGGCCCCTGATCCACCCTCC 3΄ 
Exe Reverse 5΄ TGGTGCGCCAGAAGAGGGTCC 3΄ 
 
                                               
3
Dr Siyavuya Ishmael Bulani, CSIR Biosciences, P. O. Box 395, Pretoria, South Africa 
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Table 8: PCR reaction to generate standards for mRNA hybridisation assay. 
 
Solution Volume (µl) 
Lip2:Exe plasmid template (49 ng.µl
-1
) 2.5 
dNTPs (10 mM) 0.5 
Exe- Reverse primer (10 µM) 1.5 
T7-Forward primer (10 µM) 1.5 
Buffer A (5 x) 5 
2G Fast enzyme (5 U.µl
-1
) 0.1 
Distilled water Made up volume to 25 µl 
 
 
4.2.2.2 Detection of PCR product using Agarose Gel Electrophoresis and 
Quantification using the Nanodrop 
 
The PCR product was observed on a 1 % agarose gel stained with 0.5 µg.ml-1 ethidium 
bromide. The samples were mixed with 4 µl loading buffer [10 % (v.v-1) glycerol, 0.09 % (w.v-1) 
Bromophenol Blue, 0.09 % (w.v-1) Xylene cyanol ff, 10 mM Tris pH 7.6 and 10 mM EDTA]. The 
marker (5 µl, Thermo Scientific (USA) OʹGeneRuler 1 kb DNA Ladder) was used to establish if 
the 297 bp PCR fragment was present.  Agarose gel electrophoresis was run at 120 V (labnet 
power station 300 plus, USA) in 1 x TAE buffer (40 mM Tris base, 40 mM glacial acetic acid, 1 
mM EDTA, pH 8.0).  The gel was visualized using UV. The PCR product was excised from the 
gel followed by clean-up using the ZymocleanTM gel DNA recovery kit, as per manufacturer’s 
protocol. The excised gel was placed into a sterile Eppendorf tube. ADB buffer was added to the 
gel fragment at a ratio of 3:1 and incubated at 55°C for 10 min. The solution was added to a 
Zymo-spinTM column and placed onto a collection tube (2 ml). This was centrifuged for 5-10 sec 
at 13000 x g. The collection tube content was discarded. Wash buffer (200 µl) was added to the 
spin column and centrifuged for 10 sec. The collection tube content was discarded once again 
and an additional 200 µl of wash buffer was added and centrifuged at 13000 x g for 30 sec. The 
column was transferred to a sterile 1.5 ml Eppendorf tube. TE buffer (10 µl, 10 mM Tris-HCl, 
1 mM EDTA, pH 8.0.) was added to the column and centrifuged at 60 sec to elute the DNA that 
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was bound to the matrix. The eluted product was quantified using a Nanodrop UV-Vis 
Spectrophotometer (Thermo Scientific, USA).  
 
The purified PCR product was then transcribed into mRNA using the MAXIscript® Kit, as per 
manufacturing protocol. Briefly, the PCR product (± 1 µg) was added to a sterile Eppendorf 
tube, followed by 2 µl 10 x transcription buffer, 1 µl 10 mM ATP, 1 µl 10 mM CTP, 1 µl 10 mM 
GTP, 1 µl 10 mM UTP and 2 µl Enzyme mix. The reaction mixture was made up to 20 µl with 
nuclease-free water. The tube was gently mixed and briefly centrifuged to collect the mixture at 
the bottom. Turbo DNase (1 µl) was added to the reaction and mixed well followed by incubation 
at 37°C for 15 min. The reaction was stopped by the addition of 0.5 M EDTA. An aliquot (5 µl) 
was run on a formaldehyde agarose gel (section 4.2.2.3) and the remaining solution was 
subjected to ethanol precipitation to remove any unbound nucleotides (section 4.2.2.4). The 
RNA product was quantified using the Nanodrop UV-Vis Spectrophotometer (Thermo Scientific, 
USA) and aliquots of 100 fmol stocks were stored at -80°C. 
 
4.2.2.3 Detection of RNA standard using Formaldehyde Agarose Gel 
Electophoresis  
 
An aliquot (5 µl) of the transcribed RNA was run on a 1.2 % (v.v-1) formaldehyde agarose (FA) 
gel. Agarose (12 g.l-1) was mixed with 10 x FA gel buffer (200 mM 
3-[N-morpholino]propanesulfonic acid (MOPs) (free acid), 50 mM sodium acetate, 10 mM 
EDTA, pH 7.0 using sodium hydroxide). The buffer was made in DEPC-treated water which is 
RNAse free. This water was prepared by adding DEPC (Diethylpyrocarbonate, 1 ml) to 1 l dH2O 
(distilled water) and incubated at room temperature for 1 h followed by autoclaving for 20 min at 
121°C. The agarose solution was heated to melt the agarose and cooled to 65°C using a water 
bath. For a 100 ml solution, 1.8 ml of 37 % (v.v-1) formaldehyde and 1 µl of ethidium bromide 
(10 mg.ml-1) were added. The solution was mixed by gently swirling for 5 sec and then poured 
into a gel casting support. Once the gel was set, it was equilibrated with 1 x FA gel running 
buffer (100 ml 10x FA gel buffer, 20 ml 37% (v.v-1) formaldehyde, 880 ml DEPC-treated water) 
for 30 min. The samples were mixed with 5x loading buffer (16 µl saturated aqueous 
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bromophenol blue solution, 80 µl 500 mM EDTA (pH 8), 720 µl 37% (v.v-1) formaldehyde, 2 ml 
100 %(v.v-1) glycerol, 3.1 ml formamide, 4 ml 10 x FA gel buffer and DEPC-treated water to a 
final volume of 10 ml) at a ratio of 4:1. The samples were mixed by vortexing for 5 sec and 
incubated at 65°C for 5 min. This was then transferred onto ice for 5 min. It was then loaded 
onto the equilibrated FA gel along with a marker (RiboRuler High Range RNA ladder, Thermo 
Scientific, USA). The gel was run in 1x FA gel running buffer at 40 V for 2 h.   
 
4.2.2.4 Ethanol precipitation of RNA to remove unbound nucleotides and 
quantification using the Nanodrop 
 
DEPC-treated water (30 µl) was added to the transcription reaction (20 µl) to bring the final 
volume to 50 µl in an Eppendorf tube.  In order to facilitate precipitation, 5 µl of 5 M Ammonium 
acetate was added. The contents were then vortexed for 5 sec to ensure even distribution. 
Ethanol (100 %,v.v-1) was added to the tube to a final volume of 165 µl. The solution was chilled 
at -20°C for 30 min.  The tube was centrifuged at 13000 X g for 15 min at 4°C. The supernatant 
was carefully discarded and the pellet washed with 4⁰C 70 % (v.v-1) ethanol. The tube was 
centrifuged briefly (13000 X g for 5 min). The supernatant was discarded and the tube left to air 
dry in a laminar flow for 1 h to remove the excess ethanol. The RNA was quantified using the 
NanoDrop UV-Vis Spectrophotometer (Thermo Scientific, USA).  
 
4.2.3 Optimisation of mRNA sandwich hybridization method 
 
The mRNA sandwich hybridization assay was optimised by evaluating three different 
hybridization solutions (Table 9). Standards (0, 10, 20, 40 and 60 fmol diluted from a 100 fmol 
stock) were used as samples during the optimization. Solutions A, B and C (86 µl per sample) 
were prepared fresh in a reaction tube. DIG-tail labeled detection probe (1 µl), biotin-labeled 
capture probe (1 µl), helper 1 probe (1 µl) and helper 2 probe (1 µl) was added for each reaction 
into the reaction tube. Each hybridization solution was tested with 20 µg or 50 µg of magnetic 
beads. 
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Each solution (90 µl containing the hybridization solution and probes) was added to a well (n = 
3) of a 96 well clear reaction plate (flat - bottom). The plate was incubated using a thermomixer 
(Eppendorf Thermomixer® comfort, Germany) at 60°C for 5 min (650 rpm). The sample (10 µl) 
was added into each well containing the hybridization solution. The plate was placed in the 
thermomixer for 40 min at 650 rpm, 60°C (temperature was determined using Tm values of 
probes to prevent non-specific binding - see table 6). Magnetic beads [Streptavidin 
MagneSphere® Paramagnetic Particles (Promega, USA)] were prepared by adding the volume 
of beads required (20 µg or 50 µg per reaction well) in an Eppendorf tube. The tube was placed 
onto a Magnesphere® Magnetic Separation Stand (Promega, USA) to allow the removal of the 
supernatant. The supernatant was discarded and 5 x SSC (Saline-Sodium Citrate buffer) buffer 
(diluted from a 20 x stock using DEPC treated water: 3 M NaCl and 0.3 M sodium citrate, pH 
7.0) was added. The tube was vortexed for 5 sec and placed on the separation stand. This was 
repeated twice and the magnetic bead solution finally made-up to the original volume using 5 x 
SCC. Streptavidin Magnetic beads (20 or 50 µl) were added into each well containing the 
hybridization solution and sample. The target RNA molecules were immobilized onto the 
streptavidin magnetic beads by incubating in the thermomixer for 30 min at 60°C (650 rpm). 
After immobilization the wells were washed by placing the reaction plate onto a MagnaBot® 96 
Magnetic Separation Device (Promega, USA)and allowing the beads to be collected for 1 min. 
The liquid was removed from the wells and 150 µl of washing solution (1 x SSC, 0.01 % (m.v-1) 
SDS and 0.1 % (v.v-1) TWEEN20) was added. The plate was incubated in the thermomixer for 
2 min at 25°C (650 rpm). This washing step was repeated three times. 
 
Diluted anti-DIG Alkaline Phosphatase Fab-fragments (100 µl) was added to each well. The 
plate was incubated in the thermomixer at 25°C at 750 rpm for 5 sec and then decreased to 450 
rpm for 30 min. The reaction plate was again placed onto a MagnaBot® 96 Magnetic Separation 
Device for 1 min and the washing step was repeated for three times as described above. After 
the 3rd washing step, both the liquid and beads were transferred to a new reaction plate to avoid 
signal from the anti-DIG Alkaline Phosphatase that was bound to walls. The new plate was 
incubated for 2 min at 25°C with 750 rpm shaking. The plate was again placed onto a 
MagnaBot® 96 Magnetic Separation Device and the liquid removed followed by washing of the 
beads once more. The substrate [100 µl, AttoPhos® fluorescent substrate (Promega, USA)] was 
added into each well and incubated in the thermomixer at 37°C at 1100 rpm for 5 sec and 
decreased to 750 rpm for 20 min. The plate was placed onto the MagnaBot® 96 Magnetic 
Stellenbosch University  https://scholar.sun.ac.za
48 
 
Separation Device for 1 min and 90 µl of the liquid (not beads) was transferred to a black 
reaction plate (96 well, flat bottom) for fluorescence measurement. The fluorescence signals 
were measured with a Victor 2 Fluorescence reader (Perkin Elmer Wallac, USA) at an excitation 
wavelength of 485 nm and an emission wavelength of 535 nm. 
 
Table 9: Components of hybridization solution used to optimise mRNA assay. 
 
Solution Components per well (90 µl) Reference 
A 25 µl 20x SSC buffer,  
2 µl 10% (m.v
-1
) SDS  
(Sigma-Aldrich,USA) , 
  
15 µl 20 % (m.v
-1
) Dextran sulphate 
(Sigma-Aldrich,USA),  
2 µl 50x Denhardts reagent (Life 
Technologies, USA) and  
42 µl DEPC-H2O 
Rautio et al., 2006; 2007 
B 25 µl 20x SSC,  
5 µl 10% (m.v
-1
) SDS,  
20 µl 20 % (m.v
-1
) Dextran sulphate,  
2 µl 50x Denhardts reagent,  
20 µl Formamide and 
14 µl DEPC-H2O 
Rautio., 2003 
C 25 µl 20x SSC,  
20 µl Formamide, 
15 µl 20 % (m.v
-1
) Dextran sulphate,  
2 µl 10 % (v.v
-1
) TWEEN20, 
1 µl 100x Denhardts reagent, 
10 µl 10x blocking reagent,  
13 µl DEPC-H2O. 
Thieme et al., 2008 
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4.2.4 Optimisation of cell breakage 
4.2.4.1 Harvesting of cells 
 
In order to harvest the same amount of cells, an OD versus cell count relationship had to be 
determined.  Cells were harvested from a flask and their OD at 660 nm was determined using 
the spectrophotometer. Serial dilutions were made and 100 µl of sample spread onto PCA 
plates. The OD:cell count ratio was used to ensure a constant number of cells was harvested 
every time. An Eppendorf tube, containing the constant number of cells, was centrifuged at 
13000 x g at 4°C (Sigma Laborzentrifugen 1K15). The supernatant was discarded and the pellet 
washed with 1 ml DEPC-treated water. The suspension was centrifuged again at 13000 x g at 
4°C. The supernatant discarded and the pellet was snap-frozen using liquid nitrogen (200 ml) 
and stored at -80°C. 
 
4.2.4.2 Different cell breakage buffers 
 
Different buffers were used to optimise cell breakage. Once the pellet was defrosted, 500 µl of 
each buffer (Table 10) was added to the Eppendorf tube. The contents of each Eppendorf tube, 
containing the different buffers, were transferred to a homogenizer tube containing acid washed 
glass beads (0.5g, 425 - 600 µM, section 3.2.4.3). This suspension was disrupted for 2 min at 
6.0 m.s-1(MP tm FastPrep (R)-24 homogenizer) and then centrifuged at 13000 x g for 10 min at 
4°C. The supernatant (400 µl) was aliquoted into four (100 µl) sterile Eppendorf tubes (2 ml) and 
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Table 10: Different buffers evaluated  for cell breakage. 
 
Buffer Components 
Lysis buffer 5x SSC buffer,  
4% SDS and  
1 µl.ml
-1
 RNA guard RNAse inhibitor 
TEN buffer 200 mM Tris-HCl buffer (pH 8),  
2 mM EDTA,  
200 mM NaCl and  
1 µl.ml
-1
 RNA guard 
Y-PER ((Thermo Scientific, USA)) 
and TEN buffer combination 
Y-PER (250 µl) was added to the pellet and the 
tube was incubated at 25°C, 650 rpm using the 
Eppendorf Thermomixer® comfort (Germany) for 
30 min.  
TEN buffer (250 µl) was added to suspension. 
 
  
4.2.4.3 Acid washing of Glass beads 
 
Glass beads (425-600 µM) used for cell breakage, were prepared by adding 100 g of glass 
beads in a 250 ml Schott bottle. HCl (100 ml, 5.8 M, v.v-1) was added to the bottle until the 
beads were covered. The content of the bottle were incubated at room temperature (25°C) for 
1 h.  The HCl was carefully removed and sterile 160 ml of dH2O was added. The bottle was 
swirled for 10 sec to ensure the beads were mixed. Once the beads sank to the bottom, the 
water was carefully removed. This wash was repeated 10 times. The beads were autoclaved for 
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4.2.5 Shake flask study to evaluate the mRNA sandwich hybridization 
assay 
 
Ultra yield flasks (2.5 l) containing 700 ml YPD medium, pH 6.8, were prepared and autoclaved 
at 121°C for 20 min.  Each flask was inoculated using a single cryo-vial from the cell bank. The 
temperature was maintained at 28°C and the flasks were left shaking at 180 rpm. Growth and 
mRNA transcription were followed by taking samples (10 ml) at regular time intervals. Growth 
was measured by determining the optical density at 660 nm.   
 
Based on the optical density, a constant amount of cells were centrifuged at 13000 x g for 10 
min at 4°C (section 4.2.4.1).  Upon harvesting, cells were broken using the Y-PER-TEN Buffer 
method (section 4.2.4.2). The frozen supernatant was then defrosted and hybridization solution 
C (refer to Table 9) using 20 µl of beads (based on optimised studies), was used for the mRNA 
assay (section 4.2.3). A transcription and growth (OD660nm) profile was hence established. 
 
4.3 Results and Discussion 
 
4.3.1 Generation of standards for mRNA sandwich hybridization assay 
 
mRNA transcripts of known concentrations needed to be generated for a standard curve. PCR 
was used to upscale the quantity of the Lip2:Exe fragment. After PCR, agarose gel 
electrophoresis (Figure 15) was used for detection of the product followed by quantification 
using the Nanodrop. 




Figure 15: Detection of PCR product using agarose gel electrophoresis. Agarose gel indicating the 297 
bp fragment of the Lip2:Exe fragment attached to a T7 promoter produced during PCR. 
 
After quantification using the nanodrop, the PCR product was transcribed into RNA using the 
MAXIscript® Kit. An aliquot of the reaction was run onto a formaldehyde agarose gel for 
detection of the 297 bp Lip-Exe fragment (Figure 16). The components of the transcription 
reaction were precipitated with ethanol to remove any unbound nucleotides and the pure RNA 
quantified using the Nanodrop. This RNA sample could now be used as a standard to quantify 
Lip2:Exe transcripts with the sandwich hybridization assay.  
 
Figure 16: Detection of transcribed PCR product using formaldehyde agarose gel electrophoresis. 
Formaldehyde agarose gel indicating the 297 bp fragment of the transcribed Lip2:Exe fragment. 
 
PCR product (297 bp) 
Transcribed PCR product (297 bp) 
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4.3.2 Optimization of mRNA sandwich hybridization method 
 
Probes were designed for the mRNA sandwich hybridization assay (Table 6). The biotin-labelled 
probe was used for capturing the Lip2:Exe mRNA transcripts onto the streptavidin magnetic 
beads and the DIG-labelled probe used for detection. Anti-DIG Alkaline Phosphatase Fab 
fragments were then used to quantify the amount of mRNA transcripts generated under the 
regulation of the hp4d promoter. It has been shown that the use of helper probes assist in 
binding of the DIG and biotin-labelled probes (Barken et al., 2004). Following the generation of 
the mRNA Lip2:Exe fragments of known concentration, this was used as a standard to evaluate 
three sandwich hybridization assays methodologies for repeatability (Figure 17). In addition, two 
streptavidin magnetic bead concentrations (20 and 50 µg per sample) were tested to define 
maximum binding capacity (Figure 17).  
 
The same standards of mRNA Lip2:Exe fragments (0, 10, 20, 40 and 60 fmol diluted from a 100 
fmol stock) were used for each protocol. The binding capacity of the 50 ug beads using protocol 
A was not linear with a R2 value of 0.846 (Figure 17A). The linearity of the 20 µg magnetic 
beads was higher with an R2 of 0.9672. Protocol B (Figure 17B) showed a ±50 % difference (in 
fluorescence intensity between the two bead concentrations. R2 values were 0.9989 and 0.9639 
for the 50 µg and 20 µg respectively. Protocol C (Figure 17C) showed almost similar 
fluorescence intensities for both concentrations of magnetic beads. The 20 µg beads reached 
their maximum binding capacity at 40 fmol whereas the binding capacity of the 50 µg beads was 
linear up to 60 fmol, the highest concentration tested. Protocol C, at a streptavidin magnetic 
bead concentration of 20 µg, was therefore chosen for the mRNA sandwich hybridisation assay. 
The reason being that the binding capacity in terms of the components of the assay was similar 
for both bead concentrations therefore it was more cost effective to chose the 20 µg over the 50 
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4.3.3 Optimization of cell breakage 
 
Once the sandwich hybridisation assay was optimised using the Lip2:Exe mRNA standard, the 
repeatability of cell breakages of samples, taken at various time points, was tested. Firstly, an 
OD: cell ratio was determined and used as a constant to ensure that the same number of cells 
are harvested for every sample. The determined OD constant was 4, equalling 1.2 x 108 
cells.ml-1. The first buffer tested (Figure 18) was the lysis buffer (Table 10). 
 
The standard deviation between flasks using the lysis buffer was high indicating inefficient cell 
breakage and results were not repeatable (Figure 18). It was also noticed that white precipitate 
formed after beads were used to break the cells. This interfered with the contents of the 
samples as observed by the high standard deviations for each sample. This buffer was 
therefore not used further. Y-PER, an enzyme that degrades the cell walls of yeast, TEN buffer 
and a Y-PER-TEN buffer combination were tested in combination with mechanical cell breakage 
(Figure 19). All three solutions showed repeatable cell breakage. Y-PER showed repeatability 
but the fluorescence intensity was low indicating the solution lacked components necessary for 
an optimal sandwich hybridisation assay. A combination of Y-PER and TEN buffer yielded the 
highest fluorescence intensity and was therefore selected for cell breakage. 
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Figure 17: Comparison of three different protocols 
magnetic bead concentrations 50 µg (
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Figure 18: Variation of Fluorescence intensity after cell breakage of Y. lipolytica cells during cultivation in 





Figure 19: Replicates of a sample using different cell breakage solutions. Y-PER (red), TEN buffer (blue) 
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4.3.4 Shake flask study to evaluate the mRNA sandwich hybridization 
assay  
 
After optimisation of the assay and cell breakage, a flask trial was used to validate the assay for 
repeatable mRNA transcriptional trends of the hp4d promoter (Figure 20). The growth of the 
organism (n = 3) was also measured at OD660nm (Figure 20). The assay was reproducible (each 
sample was done in quadruplicate) with different flasks showing similar results (as observed by 
the error bars). It can be seen that the production of mRNA (Figure 20) took place throughout 
the growth of Y. lipolytica (Figure 20). This shows that the hp4d promoter is quasi-constitutive. 
The amount of Lip2:Exe mRNA transcripts increased during the exponential phase and as the 
organism switched from exponential to stationary phase, the amount of mRNA transcripts, 
started to decrease.  A possible explanation could be that during exponentional phase, 
metabolism of the organism is high and hence a spike is observed due to freely available amino 
acids present in the medium for transcription. Once metabolism started slowing down, the 
amount of Lip2:Exe mRNA transcripts started, under regulation of the hp4d promoter, to decline.  
However, when compared to Figure 9B, extracellular lipase and protein production started once 
the organism reached early stationary phase. According to Fickers et al. (2004) and Fickers et 
al. (2011), during the exponentional growth phase of Y. lipolytica, extracellular lipase is 
associated with the cell wall and is only released into the culture broth at the end of the 
exponentional growth phase. This would explain why the lipase activity is only observed during 
early stationary phase once metabolism slows down and transcription of the Lip2:Exe mRNA, 
under regulation of the hp4d promoter is observed during exponential growth phase.  
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Figure 20: Growth profile () and v
shake flask production of Lip2:E
time profiles during growth of Y. lipolytica
4.4 Concluding Remarks
 
It was important to monitor mRNA transcription of the Lip2:Exe gene in order to understand the 
regulation of the hp4d promoter. Measuring the activity of lipase, although, gave an indication of 
the amount of the mRNA transcripts translated, it did
due to degradation). It also did not explain if 
transcription which would be due to the promoter or at the level of translation which would be 
due to metabolism. Therefore a
mRNA transcripts produced during the growth of 
promoter. The methodology was optimized for cell breakage and for the hybridization assay 
followed by validation using a flask study. 
time-consuming as opposed to northern hybridization and it did not require RNA free from DNA 
contaminants as opposed to RT
The results obtained from the flask trial 
order to evaluate effect of growth
alidation of mRNA sandwich hybridisation assay protocol
xe fusion by Y. lipolytica. Flasks showed the same repeatable trend for 
 expressing fused Lip2-Exe. 
 
 
 have several limitations (activity decrease 
recombinant production was at the level of 
 methodology was developed to quantify the amount of LIP2:Exe 
Y. lipolytica under regulation of the hp4d 
Compared to other methodologies, the assay was not 
-PCR which made it more cost efficient (
showed that the hp4d promoter is 
 under regulation of the hp4d promoter during fed
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 () during 
Thieme et al., 2008). 
quasi-constitutive. In 
-batch 
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cultivation, continuous fermentation will be used to control growth rate and the amount of 


















Chapter 5: Determining the effect 
of growth rate on the regulation of 
the hp4d promoter by monitoring 
mRNA transcription 
 





Yarrowia lipolytica is used as an expression host for the production of heterologous enzymes. A 
Y. lipolytica (YlEx-gly) strain with the potential to express the exenatide peptide was developed. 
Exenatide is a therapeutic drug used as an alternative to insulin for the treatment of type 2 
diabetes. The Lip2 expression cassette which consisted of the Lip2 gene, 6 X Histidine tag, an 
enterokinase cleavage site, the exenatide peptide and a glycine amino acid (Figure 6) was 
integrated into the genome of Y. lipolytica (YlEx-gly). This was expressed under the regulation 
of the synthetic quasi-constitutive hp4d promoter (Chapter 3). The CSIR is developing a process 
for the recombinant production of pharmaceuticals peptides in Y. lipolytica. According to 
literature, the hp4d promoter was said to be growth phase dependent hence it is switched on 
during early stationary growth phase of Y. lipolytica (Madzak et al., 2000; Nicaud et al., 2002). 
However, the production of lipase, under regulation of the hp4d promoter was elucidated in 
continuous fermentation and found to be linked to growth rate with high product production 
occurring at growth rates lower than 0.045 h-1 (van Zyl, 2013). During optimisation of a 
methodology to monitor mRNA transcripts under regulation of the hp4d promoter, it was 
observed that transcripts were produced throughout the exponential and stationary growth 
phases of Y. lipolytica during batch cultivation (Chapter 4) and therefore could not be growth 
phase dependent. It is, however, unclear if this regulation is at the level of transcription or 
cellular metabolism and how mRNA transcription would be affected during fed-batch 
fermentation cultivations under controlled growth conditions. In order to determine the effect of 
growth rate on transcription levels of the gene under regulation of the hp4d promoter, Y. 
lipolytica will be cultivated in continuous fermentation at different growth rates using carbon 
limitation as the growth regulator. Subsequently total extracellular protein production using fed-
batch fermentation will be compared at different growth rates to validate the results obtained 
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5.2 Materials and Methods 
 
5.2.1 Determination of carbon to nitrogen ratio to achieve carbon limitation 
 
Erlenmeyer flasks (n = 3), containing sterile medium (autoclaved at 121°C for 20 min) of 20 g.l-1 
yeast extract and different glucose concentrations (Table 11), were each inoculated with cells of 
Y. lipolytica  YlEx-gly from a 2 ml cryo-vial from the cell bank. The flasks were incubated at 28°C 
and 180 rpm on a shaking incubator. After 18 h (late exponential growth phase as determined 
by growth curve study) samples were taken hourly until constant OD (660 nm) was reached. 
The residual glucose was measured for each sample. Once stationary phase was reached 
(constant OD for three successive samples), 2 ml of the broth was centrifuged at 13000 x g for 
10 min in pre-weighed Eppendorf tubes. The supernatant was decanted and the pellet left to dry 
in an oven at 50°C. The Eppendorf tubes were weighed and the biomass determined for each 
sample. The biomass yield on glucose utilized was determined by measuring the amount of 
biomass per glucose utilized (g.l-1 of biomass/ g.l-1 of glucose). The ratio of carbon to nitrogen 
was determined for a carbon limitation medium required for continuous fermentation. 
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) 
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5.2.2 Evaluation of the effect of different growth rates on the production of 
fused Lip2:Exe by Y. lipolytica during continuous fermentation  
 
A 2 l continuous fermenter (Infors HT, Switzerland) containing sterilise (autoclaved for 45 min at 
121°C) 1.2 l modified CSIRman medium (20 g.l-1 yeast extract, 20 g.l-1 glucose and 1 ml.l-1 
antifoam, pH 6.8) was aseptically inoculated via the septated port with cells of Y. lipolytica YlEx-
gly from a 2 ml cryo-vial from the cell bank using a sterile syringe. The pH was controlled at 6.8 
with 25% NH4OH (m.v
-1) or 25% H2SO4 (m.v
-1). The temperature was controlled at 28°C, 
aeration at 2 slpms and agitation at 1000 rpm. In order to determine when mid-exponential 
phase was reached, OD660nm was measured by taking 2 ml samples. The feed (20 g.l
-1 yeast 
extract and 20 g.l-1 glucose) was then started. The feed was controlled to maintain growth rates 
ranging from 0.012 – 0.049 h-1. Monoculture was checked microscopically on a daily basis. 
Once steady state was reached, for each growth rate, as indicated by constant protein 
production (Chapter 3, section 3.2.4.2) and OD660nm for three retention times, a sample (10 ml) 
was taken for analysis. Biomass (Chapter 3, section 3.2.4.1), OD, enzyme activity (Chapter 3, 
section 3.2.4.3), extracellular protein concentration (Chapter 3, section 3.2.4.2), residual 
glucose concentration and mRNA transcription profiles (Chapter 4, sections 4.2.4.1, 4.2.4.2 and 
4.2.3) were established. To validate the results obtained during continuous fermentation, the 
production of total extracellular protein by fed-batch fermentations, at different growth rates, was 
compared. 
 
5.2.3 Evaluation of different feed rates to maintain the growth rate during 
Fed-batch fermentation of Y. lipolytica under regulation of the hp4d 
promoter 
 
5.2.3.1 Inoculum for fed-batch fermentation 
 
Fernbach flasks (2 L) containing 700 ml sterile YPD medium (autoclaved for 20 min at 121°C), 
were inoculated with cells of Y. lipolytica YlEx-gly from a 2 ml cryo-vial from the cell bank 
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followed by incubation on an orbital shaker at 28°C and 180 rpm. Once mid-exponential phase 
(OD660nm: 1-3; Age: 16-18 h) was reach, the contents of these flasks were used to inoculate the 
fermenters. 
 
5.2.3.2 Fed-batch fermentation 
 
Biostat C fermenters (15 l, Germany) containing 6.5 l of modified CSIRman medium (30 g.l-1 
glucose, 30 g.l-1 yeast extract and 1 ml.l-1 antifoam) were sterilised at 121°C for 45 min. The pH 
was automatically controlled at pH 6.8 with 25 % NH4OH (v.v
-1) or 20 % H2SO4 (v.v
-1). After 
inoculation of each fermenter, agitation started at 500 rpm and was ramped up hourly (100 rpm 
intervals) to maintain the pO2 at 30 % saturation. The temperature was controlled at 28°C and 
airflow at 2 slpms. Once residual glucose was depleted, the feed (200 g.l-1 glucose and 200 g.l-1 
yeast extract) was started and fed at a rate to maintain the growth rates of choice (0.019- 0.049 
h-1). Samples (20 ml) of culture broth were aseptically removed, at regular intervals, to measure 
pH, residual glucose concentration, biomass production (Chapter 3, section 3.2.4.1) and 
OD660nm. Triplicate (2 ml) samples were centrifuged at 13000 x g for 10 min. The supernatant 
was dispensed into sterile Eppendorf tubes and stored at -20°C for quantification of total 
extracellular protein (Chapter 3, section 3.2.4.2). Monoculture status was checked daily, 
microscopically. 
 
5.3 Results and Discussion 
 
5.3.1 Determination of carbon to nitrogen ratio to achieve carbon limitation  
 
The study was done to determine the ratio of yeast extract to glucose to ensure carbon 
limitation necessary for continuous fermentation. At initial charge glucose concentrations higher 
than 20 g.l-1, the glucose concentration was not yet depleted at the start of stationary growth 
indicating that nitrogen had become the growth limiting nutrient in the medium. In batch cultures, 
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where both nitrogen and carbon are present in medium, nitrogen is consumed first as soon as 
growth starts (Beopoulos et al., 2009). In order to prevent citric acid production, the ratio of 
carbon to nitrogen consumption is essential (Beopoulos et al., 2009). The biomass yield on 
glucose utilized decreased, as the residual glucose in the medium increased to a concentration 
of 20 g.l-1 (Figure 21). At higher glucose concentrations (30 to 40 g.l-1) the yield was constant at 
1.6 g.g-1 (± 0.2).  It can be observed from the yield of biomass on glucose utilised, at 10 g.l-1 
glucose becomes the limiting factor. It was determined to ensure a glucose limited medium 20 
g.l-1 of glucose will be used therefore the ratio of glucose to yeast extract should be 1.1.  
 
 
Figure 21: The effect of different glucose concentrations on the growth of Y. lipolytica (YlEx-gly) in shake 
flasks at 20 g.l
-1
 yeast extract concentration. Residual glucose concentration at the end of exponential 
growth() and the yield of Y. lipolytica biomass on glucose utilised  (). 
 
5.3.2 The effect of different growth rates on the production of fused 
Lip2:Exe by Y. lipolytica during continuous fermentation  
 
Continuous fermentation was used to observe the effect of growth rate on the regulation of the 
hp4d promoter during the production of fused Lip2:Exe under carbon limitation. Glucose 
limitation was used to maintain different growth rates between 0.01 and 0.05 h-1 by changing the 
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time and the OD and protein concentrations measured to determine steady state at the desired 
dilution rate. Once steady state was confirmed by three constant values, the fermenters were 
sampled and analysed for biomass, lipase and protein production before changing the dilution 
rate (Figure 22). Biomass remained constant at 13.16(± 1.12) g.l-1 and the residual glucose was 
below detection levels at the dilution rates evaluated (Figure 22A). The lipase activity (used as a 
reporter enzyme) and total extracellular protein gave an indication of the amount of fused 
Lip2:Exe produced (Figure 22B). Similar trends were observed for extracellular lipase activity 
and protein production. Volumetric lipase production increased from 2734.26 (± 100.50) to 
3314.14 (± 283.79) nKat.ml-1 when the growth rate increased from 0.01 to 0.02 h-1. When the 
growth rate was increased above 0.02 h-1 to 0.03 h-1 the lipase activity decreased 3.7 fold to 
900.65 (± 16.15) nKat.ml-1 followed by a further 2.3 fold decrease to 398.90 (± 16.92) nKat.ml-1 
at a growth rate of 0.05 h-1. Total protein also followed the same trend as the lipase activity. An 
increase from 0.502 (± 0.015) to 0.554 (± 0.008) mg.ml-1 was observed when the growth rate 
was increased from  0.01 to 0.02 h-1 followed by a 1.3 fold decrease of 0.433 (± 0.003) mg.ml-1 
at a growth rate of 0.03 h-1. When the growth rate was increased from 0.02 to 0.05 h-1 the lipase 
activity decreased 8.3 fold and the extracellular total protein concentration decrease 1.6 fold. 
The highest lipase and total extracellular protein concentration was produced at a growth rate of 
0.02 h-1.  
  





Figure 22: The effect of growth rate on biomass and Lip2: Exe production by Y lipolytica (YlEx-gly) grown 
in continuous fermentation. A: biomass () and residual glucose concentration (). B: Lipase activity () 
and protein concentration ()  
 
To determine if the increase in total protein concentration was due to increased production of 
protein under the hp4d promoter the volumetric lipase productivity was compared to specific 
lipase activity at different growth rates (Figure 23A). The specific lipase activity increased from 
5448.53 to 5980.76 nKat.mg-1protein when the growth rate was increased from 0.01 to 0.02 h
-1 
followed by a 5.3 fold decrease in specific activity to 1138.43 nKat.mg-1protein at a growth rate of 
0.05 h-1. Using the optimised conditions for the mRNA sandwich hybridisation assay, the 
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and this was compared to volumetric lipase productivity (Figure 23B). The amount of mRNA 
transcripts.g-1 in⁰reased from 10385.04 to 14217.98 fmol.g-1 when the growth rate was 
increased from 0.01 to 0.02 h-1 followed by a rapid 14.5 fold decrease to 980.16 fmol.g-1 at a 
growth rate of 0.03 h-1. A further increase in growth rate to 0.05 h-1 did not have an effect on the 
level of transcription of the hp4d promoter.  
 
Figure 23: The effect of growth rate (dilution) on transcription and translation during production of 
Lip2:Exe fusion by Y. lipolytica (YlEx-gly) under regulation of the  hp4d promoter. A: Specific lipase 
activity () and lipase productivity (▲). B: mRNA transcripts per gram of biomass () and lipase 
productivity (▲).  
 
Volumetric lipase productivity followed the same trend as transcription. The amount of 
transcripts produced under the regulation of the hp4d promoter decreased at growth rates 
above 0.02 h-1. The optimum growth rate for production of the Lip2:Exe fusion peptide under 
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extracellular protein production was quantified at different growth rates during fed-batch 
fermentation. 
 
5.3.3 Evaluation of different feed rates to maintain the growth rate during 
Fed-batch fermentation of Y. lipolytica under regulation of the hp4d 
promoter 
 
A fed-batch fermentation strategy was used to confirm that production of fused Lip2:Exe under 
regulation of the hp4d promoter is growth rate dependent. Four different growth rates between 
0.02 to 0.05 h-1, were compared by controlling the glucose feed (Figure 24). During the batch 
phase of the fermentation the growth, as determined by optical density and initial charge 
glucose consumption followed the same trends for all fermentations. After depletion of the initial 
charge glucose the glucose feed rate was used to maintain the growth rate of Y. lipolytica at the 
desired rates.  
 
Protein production started at the end of the exponential growth phase i.e. when the growth rate 
of the organism decreased, (Figure 24). When the production of the fused Lip2:Exe precursor, 
during fed-batch and continuous fermentation, were compared, both showed the same trends at 
different growth rates (Figure 26). As the growth rate increases, extracellular protein production 
decreased.  





Figure 24: Fed-batch fermentation of Y. lipolytica (YlEx-gly) expressing fused Lip2:Exe at different growth 
rates. Optical density (), residual glucose () and glucose feed (▲) were compared at different growth 
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Figure 25: Total extracellular protein production and optical density during fed
different growth rates. Optical density (
(YlEx-gly) expressing fused Lip2:


































) and total extracellular protein production (
Exe during fed-batch fermentation at different growth rates. A: 0.019; B: 
 




-batch fermentation at 





















Figure 26: Comparison of extracellular protein production of Y. lipolytica during Fed-Batch and 
Continuous fermentation. Production of fused Lip2:Exe by fed-batch fermentation () and continuous 




The fed-batch fermentation therefore confirmed the data obtained in continuous fermentation 
that the production of proteins under regulation of the hp4d promoter is growth rate dependent 
as reported by van Zyl (2013). By decreasing the growth rate of the organism, a 60 % increase 
in total extracellular protein production took place. Growth rate has shown to have an effect on 
the recombinant production of proteins in several yeast expression systems. This was observed 
in Saccharomyces cerevisiae during the heterologous production of human insulin precursor 
and α—amylase (Liu et al., 2013). Similar results were achieved by Madzak et al. (2005) during 
the production of a Pycnoporus cinnabarinus lac 1 gene by Yarrowia lipolytica under regulation 
of the hp4d promoter with the highest protein production taking place at the lower growth rate 
(Madzak et al., 2005).  
 
Growth rate has also shown to have an effect on secretion of human serum albumin in Picha 
Pastoris. In a glucose-limited chemostat, production was measured during growth rates of 
0.015- 0.15 h-1 of P. pastoris. At high growth rates, several transcription regulation factors 
showed to be down regulated resulting in a decrease in protein production. Maximum 
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Although transcription levels showed a brief increase during exponential growth (Figure 20), 
during batch cultivations, it was not sustained whereas growth rate had a sustainable effect on 
the level of transcription (Figure 22 and 23) during continuous and fed-batch fermentations. The 
absence of  extracellular lipase despite the increased level of transcription observed during mid 
exponential growth, during batch cultivations, can be explained by the fact that lipase secretion 
is triggered under carbon starvation or when the easily utilised amino-acids are depleted (Barth, 
2013). The data obtained during continuous and fed-batch fermentations as observed in Figures 
22, 23, 25 and 26, showed the hp4d promoter is growth rate dependent. This corresponds to the 
data achieved by van Zyl (2013). Compared to flask trial studies, the optimised fed-batch 
strategy yielded a 3.29 fold increase in total extracellular protein production.  
 
5.4 Concluding Remarks 
 
The regulation of the hp4d promoter in Y. lipolytica (YlEx-gly) was elucidated by using 
continuous fermentation to evaluate the effect of different growth rates on the regulation of the 
hp4d promoter. Transcription levels and extracellular lipase activity was measured and it was 
found that there was a direct correlation between the two and the growth rate. Maximum total 
extracellular recombinant protein production, lipase activity and mRNA transcript levels were 
observed at a growth rate of 0.02 h-1. These levels dropped sharply with increase in growth rate 
indicating that the synthetic hp4d promoter is growth rate dependent. This information was used 














Chapter 6: Conclusion and Future 
Recommendations 





A Y. lipolytica stain expressing the fused Lip2:Exe precursor was generated and cell banked. 
Recombinant protein production was validated in flask and batch fermentation (Chapter 3). It 
was observed that production by Y.lipolytica, under regulation of the hp4d promoter, took place 
during early stationary phase. In order to optimise conditions for the production, the regulation of 
the promoter needed to be established. A methodology to monitor fused Lip2:Exe mRNA 
transcripts was optimised (Chapter 4) and validated for reproducibility. It was observed that 
mRNA transcripts, under regulation of the hp4d promoter, were produced throughout the 
exponential and stationary phase during growth of Y. lipolytica (YlEx-gly) during batch 
cultivations indicating hp4d is quasi-constitutive. Continuous fermentation was used to regulate 
the growth rate of Y. lipolytica, using glucose as a limiting factor (Chapter 5). The mRNA 
transcripts, extracellular lipase activity and total protein production was monitored and all 
followed the same trends. Maximum production, under regulation of the hp4d promoter, took 
place at a growth rate of 0.02 h-1. This was confirmed by running several fed-batch 
fermentations and quantifying the amount extracellular protein at different growth rates. A 60 % 
increase in recombinant production was observed by growing Y. lipolytica (YlEx-gly) at a rate of 
0.02 h-1 as compared to other growth rates. It was therefore established that the synthetic hp4d 
promoter is growth rate dependent. 
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6.2 Future Recommendations and research outputs 
 
Ideally, this hypothesis should be tested using different Y. lipolytica strains and different reporter 
genes. During batch cultivation, the production of total protein should also be evaluated 
intracellularly, at the level of translation especially when using the Lip2 enzyme. Different 
peptides should be tested as fusions to the Lip2 gene to evaluate if size has an effect on 
recombinant production under regulation of the hp4d promoter.  
 
The developed fed-batch fermentation strategy for the production of heterologous proteins 
under regulation of the hp4d promoter by Y. lipolytica (YlEx-gly) has the potential to be used for 
the production of pharmaceutical peptides such as exenatide. This could lead to a more 
affordable treatment for type two diabetic patients that cannot afford the more expensive 
chemically produced drugs. This technology also has the potential to establish a recombinant 
production industry in South Africa and contribute to the South African bio-economy. 
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